{
    "id": 1,
    "profileName": "BRAF V600E",
    "geneVariants": [
        {
            "id": 49,
            "fullName": "BRAF V600E",
            "impact": "missense",
            "proteinEffect": "gain of function"
        }
    ],
    "profileTreatmentApproaches": [
        {
            "id": 1,
            "name": "BRAF Inhibitor",
            "profileName": "BRAF V600E"
        },
        {
            "id": 2,
            "name": "MEK1 Inhibitor",
            "profileName": "BRAF V600E"
        },
        {
            "id": 466,
            "name": "RAF Inhibitor (Pan)",
            "profileName": "BRAF V600E"
        },
        {
            "id": 467,
            "name": "MEK inhibitor (Pan)",
            "profileName": "BRAF V600E"
        },
        {
            "id": 7,
            "name": "MEK2 Inhibitor",
            "profileName": "BRAF V600E"
        }
    ],
    "createDate": "01/17/2014",
    "updateDate": "01/17/2014",
    "complexMolecularProfileEvidence": {
        "totalCount": 200,
        "complexMolecularProfileEvidence": [
            {
                "id": 12293,
                "approvalStatus": "Preclinical - Patient cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, patient-derived BRAF V600E mutant lung adenocarcinoma cells that acquired resistance to Erk inhibitor through BRAF amplification were less sensitive to SCH772984 in culture (PMID: 28714990).",
                "molecularProfile": {
                    "id": 25928,
                    "profileName": "BRAF amp BRAF V600E"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 3910,
                    "name": "lung adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 10283,
                        "pubMedId": 28714990,
                        "title": "An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28714990"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7706,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25928,
                    "profileName": "BRAF amp BRAF V600E"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7705,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25928,
                    "profileName": "BRAF amp BRAF V600E"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16588,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 16 weeks to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).",
                "molecularProfile": {
                    "id": 25928,
                    "profileName": "BRAF amp BRAF V600E"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12294,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable tumor inhibition in cell line xenograft models of BRAF V600E mutated lung adenocarcinoma cells that acquired resistance to Erk inhibitors through BRAF amplification (PMID: 28714990).",
                "molecularProfile": {
                    "id": 25928,
                    "profileName": "BRAF amp BRAF V600E"
                },
                "therapy": {
                    "id": 6430,
                    "therapyName": "Dabrafenib + SCH772984 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3910,
                    "name": "lung adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10283,
                        "pubMedId": 28714990,
                        "title": "An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28714990"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7630,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired BRAF V600E amplification (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25928,
                    "profileName": "BRAF amp BRAF V600E"
                },
                "therapy": {
                    "id": 4536,
                    "therapyName": "Cetuximab + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16585,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, amplification of BRAF V600E was identified as an acquired alteration at the time of progression (PMID: 28951457).",
                "molecularProfile": {
                    "id": 25928,
                    "profileName": "BRAF amp BRAF V600E"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6826,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23818,
                    "profileName": "BRAF V600E BRAF T529I"
                },
                "therapy": {
                    "id": 4281,
                    "therapyName": "SB590885",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6835,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23818,
                    "profileName": "BRAF V600E BRAF T529I"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6843,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23818,
                    "profileName": "BRAF V600E BRAF T529I"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6830,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23818,
                    "profileName": "BRAF V600E BRAF T529I"
                },
                "therapy": {
                    "id": 884,
                    "therapyName": "RAF265",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6840,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23818,
                    "profileName": "BRAF V600E BRAF T529I"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6833,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to SB590885 in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23816,
                    "profileName": "BRAF V600E BRAF T529N"
                },
                "therapy": {
                    "id": 4281,
                    "therapyName": "SB590885",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6837,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to PLX4720 in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23816,
                    "profileName": "BRAF V600E BRAF T529N"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6838,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to Nexavar (sorafenib)-mediated inhibition of Erk phosphorylation but were equally as sensitive to Nexavar (sorafenib)-mediated growth inhibition as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23816,
                    "profileName": "BRAF V600E BRAF T529N"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "conflicting",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6841,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529N in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23816,
                    "profileName": "BRAF V600E BRAF T529N"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6829,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to RAF265 in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23816,
                    "profileName": "BRAF V600E BRAF T529N"
                },
                "therapy": {
                    "id": 884,
                    "therapyName": "RAF265",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6831,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23817,
                    "profileName": "BRAF V600E BRAF T529M"
                },
                "therapy": {
                    "id": 884,
                    "therapyName": "RAF265",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6834,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23817,
                    "profileName": "BRAF V600E BRAF T529M"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6828,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23817,
                    "profileName": "BRAF V600E BRAF T529M"
                },
                "therapy": {
                    "id": 4281,
                    "therapyName": "SB590885",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6842,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23817,
                    "profileName": "BRAF V600E BRAF T529M"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6839,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 23817,
                    "profileName": "BRAF V600E BRAF T529M"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16586,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, BRAF V47_D380del (reported as deletion of exons 2-8) was identified as an acquired mutation in peritoneal metastasis at the time of progression (PMID: 28951457).",
                "molecularProfile": {
                    "id": 31704,
                    "profileName": "BRAF V47_D380del BRAF V600E"
                },
                "therapy": {
                    "id": 1917,
                    "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3564,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF V600E  treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).",
                "molecularProfile": {
                    "id": 13538,
                    "profileName": "BRAF V600E BRAF L505H"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 3825,
                        "pubMedId": 25515853,
                        "title": "Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25515853"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12153,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 28495,
                    "profileName": "BRAF V600E MAP2K1 I111N"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12149,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 28495,
                    "profileName": "BRAF V600E MAP2K1 I111N"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16597,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment demonstrated enhanced inhibition of Erk phosphorylation and growth in BRAF V600E colorectal cancer cell lines overexpressing Nras in culture (PMID: 28951457).",
                "molecularProfile": {
                    "id": 31710,
                    "profileName": "BRAF V600E NRAS over exp"
                },
                "therapy": {
                    "id": 8106,
                    "therapyName": "BGB659 + Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16594,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, overexpression of wild-type NRAS in colorectal cancer cell lines harboring BRAF V600E induced Ras activation and Braf/Craf dimerization, conferred resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture and in cell line xenograft models (PMID: 28951457).",
                "molecularProfile": {
                    "id": 31710,
                    "profileName": "BRAF V600E NRAS over exp"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8199,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 19841,
                    "profileName": "BRAF V600E PIK3CA P449T"
                },
                "therapy": {
                    "id": 1659,
                    "therapyName": "Pimasertib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8194,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 19841,
                    "profileName": "BRAF V600E PIK3CA P449T"
                },
                "therapy": {
                    "id": 4656,
                    "therapyName": "Everolimus + Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4950,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",
                "molecularProfile": {
                    "id": 19841,
                    "profileName": "BRAF V600E PIK3CA P449T"
                },
                "therapy": {
                    "id": 1305,
                    "therapyName": "Cetuximab + Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4805,
                        "pubMedId": 25838391,
                        "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8189,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 19841,
                    "profileName": "BRAF V600E PIK3CA P449T"
                },
                "therapy": {
                    "id": 871,
                    "therapyName": "Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4940,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
                "molecularProfile": {
                    "id": 19841,
                    "profileName": "BRAF V600E PIK3CA P449T"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4805,
                        "pubMedId": 25838391,
                        "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4936,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",
                "molecularProfile": {
                    "id": 19841,
                    "profileName": "BRAF V600E PIK3CA P449T"
                },
                "therapy": {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4805,
                        "pubMedId": 25838391,
                        "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 8204,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 19841,
                    "profileName": "BRAF V600E PIK3CA P449T"
                },
                "therapy": {
                    "id": 4657,
                    "therapyName": "Pimasertib + Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10288,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of Miransertib (ARQ092) and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692).",
                "molecularProfile": {
                    "id": 27343,
                    "profileName": "BRAF V600E PIK3CA H1047K"
                },
                "therapy": {
                    "id": 5456,
                    "therapyName": "ARQ092 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 8234,
                        "pubMedId": 26469692,
                        "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15868,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686), but developed progression in the liver after 11 months, and a post-progression biopsy identified the EGFR exon 19 deletion without EGFR T790M, and emergence of BRAF V600E (PMID: 30123863; NCT02108964).",
                "molecularProfile": {
                    "id": 31305,
                    "profileName": "EGFR exon 19 del BRAF V600E"
                },
                "therapy": {
                    "id": 1309,
                    "therapyName": "Nazartinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3910,
                    "name": "lung adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 13872,
                        "pubMedId": 30123863,
                        "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 15028,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a breast cancer patient with metastatic lung adenocarcinoma harboring BRAF V600E developed progressive disease after initial response to Talfinlar (dabrafenib) and Mekinist (trametinib) combination therapy, NRAS Q61K was identified as an acquired mutation after disease progression (PMID: 29631033).",
                "molecularProfile": {
                    "id": 6906,
                    "profileName": "BRAF V600E NRAS Q61K"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3910,
                    "name": "lung adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 12311,
                        "pubMedId": 29631033,
                        "title": "An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to\u00a0Dabrafenib Plus Trametinib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29631033"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16584,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 40 weeks to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS Q61K was identified as an acquired mutation at the time of progression (PMID: 28951457).",
                "molecularProfile": {
                    "id": 6906,
                    "profileName": "BRAF V600E NRAS Q61K"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2275,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).",
                "molecularProfile": {
                    "id": 6906,
                    "profileName": "BRAF V600E NRAS Q61K"
                },
                "therapy": {
                    "id": 970,
                    "therapyName": "XL888",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2956,
                        "pubMedId": 22351686,
                        "title": "The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351686"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5949,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",
                "molecularProfile": {
                    "id": 6906,
                    "profileName": "BRAF V600E NRAS Q61K"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5978,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 6906,
                    "profileName": "BRAF V600E NRAS Q61K"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2279,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",
                "molecularProfile": {
                    "id": 6906,
                    "profileName": "BRAF V600E NRAS Q61K"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2959,
                        "pubMedId": 21107323,
                        "title": "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21107323"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12152,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5821,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 134,
                        "pubMedId": 19915144,
                        "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7700,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12158,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5820,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 134,
                        "pubMedId": 19915144,
                        "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12155,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7629,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 4536,
                    "therapyName": "Cetuximab + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7703,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 4541,
                    "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7702,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7704,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21654,
                    "profileName": "BRAF V600E MAP2K1 V211D"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5994,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22046,
                    "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 3027,
                    "therapyName": "GSK2126458 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5954,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22046,
                    "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5968,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22046,
                    "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5963,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22046,
                    "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5958,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22046,
                    "profileName": "BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12160,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 28497,
                    "profileName": "BRAF V600E MAP2K1 E203K"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12166,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 28497,
                    "profileName": "BRAF V600E MAP2K1 E203K"
                },
                "therapy": {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 12161,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 28497,
                    "profileName": "BRAF V600E MAP2K1 E203K"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6895,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).",
                "molecularProfile": {
                    "id": 23996,
                    "profileName": "BRAF V600E MAP2K1 H119P"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 134,
                        "pubMedId": 19915144,
                        "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12224,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, EBI-907 inhibited growth of colorectal cancer cells harboring BRAF V600E and EGFR overexpression in culture (PMID: 26810733).",
                "molecularProfile": {
                    "id": 25929,
                    "profileName": "BRAF V600E EGFR over exp"
                },
                "therapy": {
                    "id": 6368,
                    "therapyName": "EBI-907",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10177,
                        "pubMedId": 26810733,
                        "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7631,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25929,
                    "profileName": "BRAF V600E EGFR over exp"
                },
                "therapy": {
                    "id": 3773,
                    "therapyName": "Selumetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15175,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a pediatric patient with anaplastic ganglioglioma harboring BRAF V600E progressed after initial response to Tafinlar (dabrafenib) treatment, and was found to have acquired a BRAF L514V in cis with BRAF V600E, which conferred dabrafenib resistance in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 5078,
                    "name": "ganglioglioma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15190,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to PLX8394-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 1041,
                    "therapyName": "PLX8394",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15195,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Mekinist (trametinib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15188,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Zelboraf (vemurafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15192,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB3245 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 7465,
                    "therapyName": "BGB3245",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 15193,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB3290 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 7464,
                    "therapyName": "BGB3290",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 15189,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Tafinlar (dabrafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15194,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SCH772984 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 15191,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to TAK-632-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
                "molecularProfile": {
                    "id": 30813,
                    "profileName": "BRAF L514V BRAF V600E"
                },
                "therapy": {
                    "id": 3300,
                    "therapyName": "TAK-632",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5960,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22037,
                    "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5956,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22037,
                    "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5966,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22037,
                    "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5950,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22037,
                    "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5992,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22037,
                    "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 3027,
                    "therapyName": "GSK2126458 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5989,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22037,
                    "profileName": "BRAF V600E NRAS A146T MAP2K1 P387S"
                },
                "therapy": {
                    "id": 4004,
                    "therapyName": "Dabrafenib + GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5979,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22097,
                    "profileName": "BRAF V600E NRAS Q61K NRAS A146T"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7002,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24281,
                    "profileName": "BRAF V600E MAP2K1 V60E"
                },
                "therapy": {
                    "id": 4351,
                    "therapyName": "VRT11E",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7056,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24281,
                    "profileName": "BRAF V600E MAP2K1 V60E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7640,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7643,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7692,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 4544,
                    "therapyName": "Dabrafenib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7642,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 751,
                    "therapyName": "Gefitinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7641,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7627,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7639,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7645,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 1709,
                    "therapyName": "Gefitinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7694,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25926,
                    "profileName": "BRAF V600E EGFR G465R"
                },
                "therapy": {
                    "id": 4542,
                    "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7025,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
                "molecularProfile": {
                    "id": 24366,
                    "profileName": "BRAF V600E MAP2K1 P162S"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6036,
                        "pubMedId": 24265154,
                        "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7030,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
                "molecularProfile": {
                    "id": 24366,
                    "profileName": "BRAF V600E MAP2K1 P162S"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6036,
                        "pubMedId": 24265154,
                        "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7027,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
                "molecularProfile": {
                    "id": 24366,
                    "profileName": "BRAF V600E MAP2K1 P162S"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6036,
                        "pubMedId": 24265154,
                        "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8569,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",
                "molecularProfile": {
                    "id": 26362,
                    "profileName": "BRAF V600E PTEN loss TP53 wild-type"
                },
                "therapy": {
                    "id": 4771,
                    "therapyName": "PD-0325901 + Sapanisertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6689,
                        "pubMedId": 26272063,
                        "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7663,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7635,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7637,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7636,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7632,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7633,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 4536,
                    "therapyName": "Cetuximab + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7664,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7621,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 3773,
                    "therapyName": "Selumetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7666,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 4542,
                    "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7665,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7634,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 25921,
                    "profileName": "BRAF V600E EGFR amp"
                },
                "therapy": {
                    "id": 4540,
                    "therapyName": "Cetuximab + Selumetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11052,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312).",
                "molecularProfile": {
                    "id": 27902,
                    "profileName": "BRAF V600E TP53 Q192K"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 9046,
                        "pubMedId": 28514312,
                        "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5991,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22042,
                    "profileName": "BRAF V600E NRAS A146T"
                },
                "therapy": {
                    "id": 3027,
                    "therapyName": "GSK2126458 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5955,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22042,
                    "profileName": "BRAF V600E NRAS A146T"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5965,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22042,
                    "profileName": "BRAF V600E NRAS A146T"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5988,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22042,
                    "profileName": "BRAF V600E NRAS A146T"
                },
                "therapy": {
                    "id": 4004,
                    "therapyName": "Dabrafenib + GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5959,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22042,
                    "profileName": "BRAF V600E NRAS A146T"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5977,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22042,
                    "profileName": "BRAF V600E NRAS A146T"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5951,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22042,
                    "profileName": "BRAF V600E NRAS A146T"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15709,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a single patient with hairy cell leukemia who relapsed after initial response to Zelboraf (vemurafenib) was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant, and demonstrated a sustained response greater than 12 months to combined Zelboraf (vemurafenib) and Cotellic (cobimetinib) treatment (PMID: 30341394).",
                "molecularProfile": {
                    "id": 31172,
                    "profileName": "BRAF V600E MAP2K1 K57T"
                },
                "therapy": {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 711,
                    "name": "refractory hairy cell leukemia",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 13685,
                        "pubMedId": 30341394,
                        "title": "Targeting MEK in vemurafenib-resistant hairy cell leukemia.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30341394"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15710,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a single patient with hairy cell leukemia harboring BRAF V600E, who relapsed after a 38 week remission in response to Zelboraf (vemurafenib) treatment, was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant (PMID: 30341394).",
                "molecularProfile": {
                    "id": 31172,
                    "profileName": "BRAF V600E MAP2K1 K57T"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 285,
                    "name": "hairy cell leukemia",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 13685,
                        "pubMedId": 30341394,
                        "title": "Targeting MEK in vemurafenib-resistant hairy cell leukemia.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30341394"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5957,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22045,
                    "profileName": "BRAF V600E MAP2K1 K59del"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5984,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22045,
                    "profileName": "BRAF V600E MAP2K1 K59del"
                },
                "therapy": {
                    "id": 3027,
                    "therapyName": "GSK2126458 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5964,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22045,
                    "profileName": "BRAF V600E MAP2K1 K59del"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5983,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22045,
                    "profileName": "BRAF V600E MAP2K1 K59del"
                },
                "therapy": {
                    "id": 4004,
                    "therapyName": "Dabrafenib + GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5980,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22045,
                    "profileName": "BRAF V600E MAP2K1 K59del"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5969,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22045,
                    "profileName": "BRAF V600E MAP2K1 K59del"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5953,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22045,
                    "profileName": "BRAF V600E MAP2K1 K59del"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10815,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",
                "molecularProfile": {
                    "id": 26356,
                    "profileName": "BRAF V600E PIK3CA H1047R"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3963,
                    "name": "thyroid carcinoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 8849,
                        "pubMedId": 27797976,
                        "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10814,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976).",
                "molecularProfile": {
                    "id": 26356,
                    "profileName": "BRAF V600E PIK3CA H1047R"
                },
                "therapy": {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                "indication": {
                    "id": 3963,
                    "name": "thyroid carcinoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 8849,
                        "pubMedId": 27797976,
                        "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 10812,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",
                "molecularProfile": {
                    "id": 26356,
                    "profileName": "BRAF V600E PIK3CA H1047R"
                },
                "therapy": {
                    "id": 5650,
                    "therapyName": "Dabrafenib + Everolimus + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3963,
                    "name": "thyroid carcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 8849,
                        "pubMedId": 27797976,
                        "title": "Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797976"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5816,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 21628,
                    "profileName": "BRAF V600E MAP2K1 I103N"
                },
                "therapy": {
                    "id": 3769,
                    "therapyName": "DEL-22379",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5811,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 21628,
                    "profileName": "BRAF V600E MAP2K1 I103N"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6075,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",
                "molecularProfile": {
                    "id": 22385,
                    "profileName": "BRAF V600E CSF1R positive"
                },
                "therapy": {
                    "id": 1339,
                    "therapyName": "Pexidartinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5274,
                        "pubMedId": 25939769,
                        "title": "Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939769"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5952,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22043,
                    "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5990,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22043,
                    "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
                },
                "therapy": {
                    "id": 4004,
                    "therapyName": "Dabrafenib + GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "conflicting",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5967,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22043,
                    "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5961,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22043,
                    "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5962,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22043,
                    "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5993,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22043,
                    "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
                },
                "therapy": {
                    "id": 3027,
                    "therapyName": "GSK2126458 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5785,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 21619,
                    "profileName": "BRAF V600E NRAS G12V"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5786,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 21619,
                    "profileName": "BRAF V600E NRAS G12V"
                },
                "therapy": {
                    "id": 3769,
                    "therapyName": "DEL-22379",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5817,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 3769,
                    "therapyName": "DEL-22379",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7662,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 4542,
                    "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7654,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7661,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 4544,
                    "therapyName": "Dabrafenib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12154,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7657,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 1917,
                    "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12151,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7655,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 4525,
                    "therapyName": "Cetuximab + Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7620,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7656,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5812,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7659,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7658,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 4541,
                    "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7660,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 21627,
                    "profileName": "BRAF V600E MAP2K1 L115P"
                },
                "therapy": {
                    "id": 4543,
                    "therapyName": "Cetuximab + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7038,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4378,
                        "pubMedId": 21383288,
                        "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12159,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4031,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 4380,
                        "pubMedId": 24448821,
                        "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4029,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 1011,
                    "therapyName": "E6201",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4380,
                        "pubMedId": 24448821,
                        "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7032,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6036,
                        "pubMedId": 24265154,
                        "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4030,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600, resulting in decreased sensitivity to Zelboraf (vemurafenib)-induced inhibition of MAPK pathway activation and cell proliferation in culture (PMID: 24448821).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4380,
                        "pubMedId": 24448821,
                        "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7037,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 4378,
                        "pubMedId": 21383288,
                        "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7003,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
                "molecularProfile": {
                    "id": 17135,
                    "profileName": "BRAF V600E MAP2K1 C121S"
                },
                "therapy": {
                    "id": 4351,
                    "therapyName": "VRT11E",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 13931,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months, and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).",
                "molecularProfile": {
                    "id": 29877,
                    "profileName": "BRAF V600E EGFR exon 19 del MET amp"
                },
                "therapy": {
                    "id": 660,
                    "therapyName": "Osimertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3910,
                    "name": "lung adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 11362,
                        "pubMedId": 29596911,
                        "title": "Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29596911"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 8568,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",
                "molecularProfile": {
                    "id": 26361,
                    "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type"
                },
                "therapy": {
                    "id": 4771,
                    "therapyName": "PD-0325901 + Sapanisertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6689,
                        "pubMedId": 26272063,
                        "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12162,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 28498,
                    "profileName": "BRAF V600E MAP2K1 P124L"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12163,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 28498,
                    "profileName": "BRAF V600E MAP2K1 P124L"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16591,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 16 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, NRAS amplification was identified as an acquired alteration at the time of progression (PMID: 28951457).",
                "molecularProfile": {
                    "id": 31708,
                    "profileName": "BRAF V600E NRAS amp"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7058,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24283,
                    "profileName": "BRAF V600E MAP2K1 G128V"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7033,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
                "molecularProfile": {
                    "id": 24283,
                    "profileName": "BRAF V600E MAP2K1 G128V"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6036,
                        "pubMedId": 24265154,
                        "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7005,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24283,
                    "profileName": "BRAF V600E MAP2K1 G128V"
                },
                "therapy": {
                    "id": 4351,
                    "therapyName": "VRT11E",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7059,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24283,
                    "profileName": "BRAF V600E MAP2K1 G128V"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12164,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 22096,
                    "profileName": "BRAF V600E MAP2K1 Q56P"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12165,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).",
                "molecularProfile": {
                    "id": 22096,
                    "profileName": "BRAF V600E MAP2K1 Q56P"
                },
                "therapy": {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10118,
                        "pubMedId": 28655712,
                        "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5982,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22096,
                    "profileName": "BRAF V600E MAP2K1 Q56P"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5976,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22096,
                    "profileName": "BRAF V600E MAP2K1 Q56P"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5975,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 22096,
                    "profileName": "BRAF V600E MAP2K1 Q56P"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16630,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) and Zelboraf (vemurafenib) combination treatment inhibited growth of colorectal cancer cells harboring BRAF V600E and overexpressing Met in culture (PMID: 27325282).",
                "molecularProfile": {
                    "id": 31715,
                    "profileName": "BRAF V600E MET over exp"
                },
                "therapy": {
                    "id": 4648,
                    "therapyName": "Crizotinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 6560,
                        "pubMedId": 27325282,
                        "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16629,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, overexpressing Met in colorectal cancer cells harboring BRAF V600E conferred resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27325282).",
                "molecularProfile": {
                    "id": 31715,
                    "profileName": "BRAF V600E MET over exp"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6560,
                        "pubMedId": 27325282,
                        "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8565,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",
                "molecularProfile": {
                    "id": 26358,
                    "profileName": "BRAF V600E PIK3CA P449T TP53 R273H"
                },
                "therapy": {
                    "id": 4771,
                    "therapyName": "PD-0325901 + Sapanisertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6689,
                        "pubMedId": 26272063,
                        "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16587,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after a partial response lasting 24 weeks to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment, NRAS G13R was identified as an acquired mutation in liver metastasis at the time of progression (PMID: 28951457).",
                "molecularProfile": {
                    "id": 31705,
                    "profileName": "BRAF V600E NRAS G13R"
                },
                "therapy": {
                    "id": 1917,
                    "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16598,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB659 and Erbitux (cetuximab) combination treatment resulted in sustained inhibition of Mek and Erk phosphorylation, lead to tumor regression in patient-derived xenograft models of colorectal cancer harboring BRAF V600E and NRAS G13R (PMID: 28951457).",
                "molecularProfile": {
                    "id": 31705,
                    "profileName": "BRAF V600E NRAS G13R"
                },
                "therapy": {
                    "id": 8106,
                    "therapyName": "BGB659 + Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 14634,
                        "pubMedId": 28951457,
                        "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11042,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
                "molecularProfile": {
                    "id": 27895,
                    "profileName": "BRAF V600E PIK3CA mut"
                },
                "therapy": {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9035,
                        "pubMedId": null,
                        "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                        "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7593,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25915,
                    "profileName": "BRAF V600E MAP2K1 P124Q"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 505,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).",
                "molecularProfile": {
                    "id": 520,
                    "profileName": "MAP2K1 Q56P BRAF V600E"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 134,
                        "pubMedId": 19915144,
                        "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 506,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).",
                "molecularProfile": {
                    "id": 520,
                    "profileName": "MAP2K1 Q56P BRAF V600E"
                },
                "therapy": {
                    "id": 1061,
                    "therapyName": "PLX4720 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 134,
                        "pubMedId": 19915144,
                        "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 183,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor, selumetinib (AZD6244), in cell culture (PMID: 19915144).",
                "molecularProfile": {
                    "id": 520,
                    "profileName": "MAP2K1 Q56P BRAF V600E"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 134,
                        "pubMedId": 19915144,
                        "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3221,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical study, EGFR S492R was detected in the post-Erbitux (cetuximab) sample from a colorectal cancer patient harboring EGFR amplification and BRAF V600E who progressed on an Erbitux (cetuximab) regimen (PMID: 22270724).",
                "molecularProfile": {
                    "id": 12768,
                    "profileName": "EGFR amp EGFR S492R BRAF V600E"
                },
                "therapy": {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 3682,
                        "pubMedId": 22270724,
                        "title": "Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270724"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 17382,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated an improved metabolic response when treated with the combination therapy of Sprycel (dabrafenib) and Tagrisso (osimertinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).",
                "molecularProfile": {
                    "id": 32523,
                    "profileName": "BRAF V600E EGFR E746_A750del"
                },
                "therapy": {
                    "id": 8472,
                    "therapyName": "Dabrafenib + Osimertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 15403,
                        "pubMedId": null,
                        "title": "Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.",
                        "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e20682"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 17381,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with advanced non-small cell lung cancer who lost EGFR T790M, but still harbors EGFR E746_A750del and acquired BRAF V600E demonstrated continued progression while being treated with the combination therapy of Sprycel (dabrafenib) and Mekinist (trametinib) (Journal of Clinical Oncology, 2019, 37, no. 15_suppl).",
                "molecularProfile": {
                    "id": 32523,
                    "profileName": "BRAF V600E EGFR E746_A750del"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 15403,
                        "pubMedId": null,
                        "title": "Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.",
                        "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e20682"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11043,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
                "molecularProfile": {
                    "id": 27896,
                    "profileName": "BRAF V600E PTEN mut"
                },
                "therapy": {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9035,
                        "pubMedId": null,
                        "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                        "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10891,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).",
                "molecularProfile": {
                    "id": 23099,
                    "profileName": "BRAF V600E PTEN loss"
                },
                "therapy": {
                    "id": 5673,
                    "therapyName": "GSK2636771 + unspecified PD-1 antibody",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4556,
                        "pubMedId": 26645196,
                        "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 6318,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).",
                "molecularProfile": {
                    "id": 23099,
                    "profileName": "BRAF V600E PTEN loss"
                },
                "therapy": {
                    "id": 1050,
                    "therapyName": "XL147",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5522,
                        "pubMedId": 25637314,
                        "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7081,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).",
                "molecularProfile": {
                    "id": 23099,
                    "profileName": "BRAF V600E PTEN loss"
                },
                "therapy": {
                    "id": 4358,
                    "therapyName": "Pictilisib + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7899,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).",
                "molecularProfile": {
                    "id": 23099,
                    "profileName": "BRAF V600E PTEN loss"
                },
                "therapy": {
                    "id": 4605,
                    "therapyName": "GDC0879 + Pictilisib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6516,
                        "pubMedId": 19276360,
                        "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1233,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a retrospective analysis, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).",
                "molecularProfile": {
                    "id": 23099,
                    "profileName": "BRAF V600E PTEN loss"
                },
                "therapy": {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 1067,
                        "pubMedId": 20664172,
                        "title": "Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20664172"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7004,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24282,
                    "profileName": "BRAF V600E MAP2K1 P124S"
                },
                "therapy": {
                    "id": 4351,
                    "therapyName": "VRT11E",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7057,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24282,
                    "profileName": "BRAF V600E MAP2K1 P124S"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7035,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).",
                "molecularProfile": {
                    "id": 24282,
                    "profileName": "BRAF V600E MAP2K1 P124S"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 429,
                        "pubMedId": 22197931,
                        "title": "Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22197931"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7061,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).",
                "molecularProfile": {
                    "id": 24282,
                    "profileName": "BRAF V600E MAP2K1 P124S"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 5840,
                        "pubMedId": 24265153,
                        "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7592,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
                "molecularProfile": {
                    "id": 25914,
                    "profileName": "BRAF V600E MAP2K1 K57E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6439,
                        "pubMedId": 25370473,
                        "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8153,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E eventually developed resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination therapy, potentially due to acquiring amplification of MET (PMID: 27325282).",
                "molecularProfile": {
                    "id": 31714,
                    "profileName": "BRAF V600E MET amp"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3709,
                    "name": "rectum mucinous adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 6560,
                        "pubMedId": 27325282,
                        "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16631,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, emergence of MET amplification was detected in colorectal cancer cells harboring BRAF V600E that acquired resistance to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment in culture (PMID: 27325282).",
                "molecularProfile": {
                    "id": 31714,
                    "profileName": "BRAF V600E MET amp"
                },
                "therapy": {
                    "id": 1917,
                    "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - resistant",
                "references": [
                    {
                        "id": 6560,
                        "pubMedId": 27325282,
                        "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8152,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E and acquired MET amplification responded to the combination treatment of Xalkori (crizotinib) and Zelboraf (vemurafenib), resulting in a rapid clinical and metabolic response (PMID: 27325282).",
                "molecularProfile": {
                    "id": 31714,
                    "profileName": "BRAF V600E MET amp"
                },
                "therapy": {
                    "id": 4648,
                    "therapyName": "Crizotinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3709,
                    "name": "rectum mucinous adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 6560,
                        "pubMedId": 27325282,
                        "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            }
        ]
    },
    "treatmentApproachEvidence": {
        "totalCount": 125,
        "treatmentApproachEvidence": [
            {
                "id": 11983,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, ASN003 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 371PD; NCT02961283).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 9947,
                        "pubMedId": null,
                        "title": "A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors",
                        "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5514,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SKLB646 inhibited proliferation and migration and induced apoptosis of triple-negative breast cancer (TNBC) cell lines in culture, and inhibited tumor growth in TNBC cell line xenograft models (PMID: 26721945).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3873,
                    "therapyName": "SKLB646",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5074,
                        "pubMedId": 26721945,
                        "title": "Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26721945"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12658,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Stivarga (regorafenib) and Erbitux (cetuximab) resulted in a clinical benefit of either stable disease or partial response in 46% (11/24) of advanced solid tumor patients, including eight patients with colorectal cancer, and one patient with head and neck cancer, one with carcinoma of unknown primary, and one with glioblastoma (PMID: 28422758; NCT02095054).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1305,
                    "therapyName": "Cetuximab + Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 10198,
                        "pubMedId": 28422758,
                        "title": "First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28422758"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6265,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DHA and Stivarga (regorafenib) synergistically inhibited survival of kidney cancer cells in culture and reduced tumor growth in kidney cancer cell line xenograft models (PMID: 26921392).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4107,
                    "therapyName": "DHA + Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 263,
                    "name": "kidney cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5514,
                        "pubMedId": 26921392,
                        "title": "Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26921392"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9823,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Stivarga (regorafenib) treatment in patients with non-small cell lung cancer resulted in stable disease (SD) in 76% (13/17) of patients, and one patient with SD experienced a progression free survival of 279 days and tumor reduction greater than 30% (J Clin Oncol 28:15s, 2010 (suppl; abstr 7585)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7646,
                        "pubMedId": null,
                        "title": "Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).",
                        "url": "http://meetinglibrary.asco.org/content/53410-74"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10376,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment did not result in significant difference in median progression-free survival (1.1 vs 1.7 months) or overall survival (HR=1.57, p=0.21) compared to placebo in patients with liposarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3382,
                    "name": "liposarcoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8763,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) improved progression free survival compared to placebo in patients with refractory advanced oesophagogastric cancer (J Clin Oncol 33, 2015 (suppl; abstr 4003)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10534,
                    "name": "stomach cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6734,
                        "pubMedId": null,
                        "title": "INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)\u2014Final overall and subgroup results.",
                        "url": "http://meetinglibrary.asco.org/content/147938-156"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8764,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) improved progression free survival compared to placebo in patients with refractory advanced oesophagogastric cancer (J Clin Oncol 33, 2015 (suppl; abstr 4003)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 5041,
                    "name": "esophageal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6734,
                        "pubMedId": null,
                        "title": "INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)\u2014Final overall and subgroup results.",
                        "url": "http://meetinglibrary.asco.org/content/147938-156"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2253,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Stivarga (regorafenib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 22421192).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1764,
                        "pubMedId": 22421192,
                        "title": "A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22421192"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4544,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) showed antitumor activity in multiple murine xenograft models derived from melanoma, renal cell carcinoma, colorectal, breast, lung, pancreatic and ovarian tumor cell lines (PMID: 21170960).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 318,
                        "pubMedId": 21170960,
                        "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9869,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (RESORCE) that supported FDA approval, treatment with Stivarga (regorafenib) following Nexavar (sorafenib) treatment resulted in improved overall survival (10.6 vs 7.8 months, HR=0.63) compared to Nexavar (sorafenib) followed by placebo in patients with hepatocellular carcinoma (PMID: 27932229; NCT01774344).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8404,
                        "pubMedId": 27932229,
                        "title": "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27932229"
                    },
                    {
                        "id": 15580,
                        "pubMedId": null,
                        "title": "Stivarga (regorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7573,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) resulted in a PFS of 2.6 months compared to .9 months with placebo in gastric adenocarcinoma patients (PMID: 27325864).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3717,
                    "name": "gastric adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6437,
                        "pubMedId": 27325864,
                        "title": "Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325864"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1082,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Stivarga, (regorafenib), inhibited tumor growth in cell line xenograft models of glioblastoma multiforme (PMID: 21170960).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 318,
                        "pubMedId": 21170960,
                        "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10378,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment resulted in improved median progression-free survival (5.6 vs 1.0 months), but no difference in overall survival (HR=0.87, p=0.79) compared to placebo in patients with synovial sarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 5485,
                    "name": "synovial sarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10377,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment resulted in improved median progression-free survival (3.7 vs 1.8 months), but no difference in overall survival (HR=0.50, p=0.056) compared to placebo in patients with leiomyosarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1967,
                    "name": "leiomyosarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1925,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III clinical trial (GRID) that supported FDA approval, Stivarga (regorafenib) demonstrated safety and improved progression free survival compared to placebo (4.8 vs 0.9 months, HR=0.27, p<0.0001) in patients with gastrointestinal stromal tumors (PMID: 23177515; NCT01271712).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9253,
                    "name": "gastrointestinal stromal tumor",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2400,
                        "pubMedId": 23177515,
                        "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23177515"
                    },
                    {
                        "id": 15580,
                        "pubMedId": null,
                        "title": "Stivarga (regorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10379,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Stivarga (regorafenib) treatment resulted in improved median progression-free survival (2.9 vs 1.0 months), but no difference in overall survival (HR=0.75, p=0.37) compared to placebo in patients with soft tissue sarcoma excluding liposarcoma, leiomyosarcoma, and synovial sarcoma (PMID: 27751846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1115,
                    "name": "sarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8403,
                        "pubMedId": 27751846,
                        "title": "Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27751846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15631,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (CONSIGN), Stivarga (regorafenib) treatment demonstrated safety profile and efficacy consistent with previous studies, median progression-free survival (PFS) was 2.7 months overall, 2.8 months in KRAS wild-type, and 2.5 months in KRAS mutant colorectal cancer patients, and with no difference in KRAS status between long and short PFS groups (PMID: 30190299; NCT01538680).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 13521,
                        "pubMedId": 30190299,
                        "title": "Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30190299"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1916,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III clinical trial (CORRECT) that supported FDA approval, Stivarga (regorafenib) demonstrated safety and improved overall survival compared to placebo (6.4 vs 5.0 months, HR=0.77, p=0.0052) in patients with refractory metastatic colorectal cancer (PMID: 23177514; NCT01103323).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 938,
                        "pubMedId": 23177514,
                        "title": "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23177514"
                    },
                    {
                        "id": 15580,
                        "pubMedId": null,
                        "title": "Stivarga (regorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 855,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, RXDX-105 (CEP-32496) was tolerable and demonstrated preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2574)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6477,
                        "pubMedId": null,
                        "title": "A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.",
                        "url": "http://meetinglibrary.asco.org/content/165045-176"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8620,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, RXDX-105 (CEP-32496) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including 2 patients with heavily pretreated non-small cell lung cancer that achieved stable disease for greater that 6 months (AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C188).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6703,
                        "pubMedId": null,
                        "title": "Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers",
                        "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/C188"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 14947,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Belvarafenib (HM95573) treatment demonstrated safety and preliminary efficacy, resulted in unconfirmed partial response in 3% (1/31) and stable disease in 29% (9/31) of patients with advanced solid tumors harboring BRAF (45%), KRAS (45%) or NRAS (10%) mutations (May 20 2016) 2570-2570; NCT02405065).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7209,
                    "therapyName": "Belvarafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 11833,
                        "pubMedId": null,
                        "title": "First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.",
                        "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10473,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, WX-554 was well-tolerated and resulted in stable disease in 59% (20/34) and prolonged stable disease for greater than 6 months in 6% (2/34) of patients with advanced solid tumors (PMID: 27693888).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1058,
                    "therapyName": "WX-554",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8522,
                        "pubMedId": 27693888,
                        "title": "A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27693888"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10502,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/II trial, Refametinib (BAY86-9766) and Gemzar (gemcitabine) combination treatment resulted in an objective response rate of 23% and a disease control rate of 73% in patients with advanced pancreatic cancer (PMID: 27975152).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5545,
                    "therapyName": "Gemcitabine + Refametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8575,
                        "pubMedId": 27975152,
                        "title": "Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27975152"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1355,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Refametinib (BAY 86-9766) was well-tolerated and displayed some evidence of clinical benefit across several tumor types (PMID: 23434733).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 888,
                    "therapyName": "Refametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1066,
                        "pubMedId": 23434733,
                        "title": "Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23434733"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6406,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination treatment of Refametinib (BAY86-9766) and Nexavar (sorafenib) in patients with advanced solid tumors resulted in a disease control rate of 65.8% (25/38), specifically, 2.6% (1/38) experienced a partial response and 63.2% (24/38) demonstrated stable disease (PMID: 26644411).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2221,
                    "therapyName": "Refametinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5562,
                        "pubMedId": 26644411,
                        "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6407,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, a patient with colorectal cancer demonstrated a durable partial response for 358 days when treated with the combination of Refametinib (BAY86-9766) and Nexavar (sorafenib) (PMID: 26644411).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2221,
                    "therapyName": "Refametinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5562,
                        "pubMedId": 26644411,
                        "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6408,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, 43.8% (7/16) of hepatocellular carcinoma patients treated with a combination of Refametinib (BAY86-9766) and Nexavar (sorafenib) demonstrated stable disease (PMID: 26644411).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2221,
                    "therapyName": "Refametinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5562,
                        "pubMedId": 26644411,
                        "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1286,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BI-847325 demonstrated safety and some efficacy in a variety of advanced solid tumors (Mol Cancer Ther 2013;12(11 Suppl):B281).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1059,
                    "therapyName": "BI-847325",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 998,
                        "pubMedId": null,
                        "title": "Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.",
                        "url": "http://mct.aacrjournals.org/content/12/11_Supplement/B281.meeting_abstract"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4497,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BI-847325 treatment resulted in stable disease in 30% (21/69) of patients with advanced solid tumors, and one partial response for 67 days in a patient with esophageal cancer (PMID: 26650227).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1059,
                    "therapyName": "BI-847325",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4389,
                        "pubMedId": 26650227,
                        "title": "A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26650227"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4073,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BI-847325 treatment resulted in stable disease in 30% (21/69) of patients with advanced solid tumors, and one partial response for 67 days in a patient with esophageal cancer (PMID: 26650227).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1059,
                    "therapyName": "BI-847325",
                    "synonyms": null
                },
                "indication": {
                    "id": 5041,
                    "name": "esophageal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4389,
                        "pubMedId": 26650227,
                        "title": "A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26650227"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9752,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of AZD8055 and Mekinist (trametinib) enhanced the sensitivity of ovarian cancer cells to ABT-737 in culture, resulting in greater apoptotic activity and cell cycle arrest when compared to Mekinist (trametinib) alone (PMID: 27980105).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5191,
                    "therapyName": "ABT-737 + AZD8055 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7524,
                        "pubMedId": 27980105,
                        "title": "The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980105"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9753,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of BEZ235 and Mekinist (trametinib) enhanced the sensitivity of ovarian cancer cells to ABT-737 in culture, resulting in decreased cell viability (PMID: 27980105).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5192,
                    "therapyName": "ABT-737 + BEZ235 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7524,
                        "pubMedId": 27980105,
                        "title": "The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980105"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9754,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Mekinist (trametinib) enhanced the sensitivity of ovarian cancer cells to ABT-737 in culture, resulting in decreased cell viability (PMID: 27980105).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5193,
                    "therapyName": "ABT-737 + MK2206 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7524,
                        "pubMedId": 27980105,
                        "title": "The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980105"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3631,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Mekinist (trametinib) and Afuresertib (GSK2110183) was not well-tolerated in patients with advanced solid tumors (PMID: 25417902).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3204,
                    "therapyName": "Afuresertib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3920,
                        "pubMedId": 25417902,
                        "title": "Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25417902"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11099,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination therapy of AMG 232 and Mekinist (trametinib) in 15 patients with metastatic cutaneous melanoma without a BRAF V600 mutation resulted in a partial response in 2 patients, stable disease in 11 patients, and progressive disease in 2 patients, and of the 15 patients, 11 experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1454,
                    "therapyName": "AMG 232 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9073,
                        "pubMedId": null,
                        "title": "Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)",
                        "url": "http://abstracts.asco.org/199/AbstView_199_181299.html"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11124,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and AZ628 resulted in greater inhibition of Mek and apoptosis in a non-BRAF V600 mutant lung cancer cell line in culture compared to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (J Clin Oncol 35, 2017 (suppl; abstr e23154)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4795,
                    "therapyName": "AZ628 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1324,
                    "name": "lung cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 9096,
                        "pubMedId": null,
                        "title": "Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer",
                        "url": "http://abstracts.asco.org/199/AbstView_199_191661.html"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1694,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, ovarian cancer patients demonstrated an objective response rate of 21% (6/21), including 1 complete response and 5 partial responses, to treatment with Buparlisib (BKM120) in combination with Mekinist (trametinib) (PMID: 25500057)",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1974,
                    "therapyName": "Buparlisib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1794,
                        "pubMedId": 25500057,
                        "title": "A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500057"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10760,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in an overall response rate (ORR) of 21% (10/47, all partial responses) and stable disease in 43% (20/47) of patients with non-small cell lung cancer (PMID: 27876675).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1264,
                    "therapyName": "Docetaxel + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8810,
                        "pubMedId": 27876675,
                        "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10761,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in partial response in 1 patient and stable disease in 3 patients within the subset of 5 evaluable patients with squamous non-small cell lung cancer patients (PMID: 27876675).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1264,
                    "therapyName": "Docetaxel + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3907,
                    "name": "lung squamous cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8810,
                        "pubMedId": 27876675,
                        "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1255,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In preclinical studies, Mekinist (trametinib) enhanced the efficacy of Adrucil (fluorouracil) in colorectal cancer cells in culture (PMID: 23438367).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1113,
                    "therapyName": "Fluorouracil + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 181,
                        "pubMedId": 23438367,
                        "title": "Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23438367"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2062,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, the combination of Mekinist (trametinib) and Gemzar (gemcitabine) demonstrated safety and preliminary anti-tumor activity in patients with advanced solid tumors (PMID: 23583440).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1269,
                    "therapyName": "Gemcitabine + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 977,
                        "pubMedId": 23583440,
                        "title": "A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23583440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3618,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib clinical trial, the combination of Mekinist (trametinib) and Gemzar (gemcitabine) demonstrated safety and preliminary anti-tumor activity in patients with advanced solid tumors, including one complete response in a patient with breast cancer (PMID: 23583440).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1269,
                    "therapyName": "Gemcitabine + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 977,
                        "pubMedId": 23583440,
                        "title": "A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23583440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1260,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, a partial response was seen in 30% (3/11) of  patients with pancreatic cancer after treatment with Mekinist (trametinib) in combination with Gemzar (gemcitabine) (PMID: 23583440).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1269,
                    "therapyName": "Gemcitabine + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 977,
                        "pubMedId": 23583440,
                        "title": "A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23583440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10474,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib/II trial, the combination of Votrient (pazopanib) and Mekinist (trametinib) demonstrated safety and resulted in partial response in 8% (2/25) and stable disease in 48% (12/25) of patients with advanced soft tissue sarcomas, but did not improve the 4 month progression-free survival rate over Votrient (pazopanib) alone (PMID: 28377484).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1310,
                    "therapyName": "Pazopanib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1115,
                    "name": "sarcoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 8528,
                        "pubMedId": 28377484,
                        "title": "Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28377484"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9080,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination of Mekinist (trametinib) and Votrient (pazopanib) effectively inhibited tumor angiogenesis and growth in cell line xenograft models of renal cell carcinoma (PMID: 26487278).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1310,
                    "therapyName": "Pazopanib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6896,
                        "pubMedId": 26487278,
                        "title": "Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26487278"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10764,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Alimta (pemetrexed) resulted in an overall response rate of 14% (6/42, all partial responses) and stable disease in 55% (23/42) of patients with non-small cell lung cancer (PMID: 27876675).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1266,
                    "therapyName": "Pemetrexed + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8810,
                        "pubMedId": 27876675,
                        "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9078,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination of Mekinist (trametinib) and Sutent (sunitinib) effectively inhibited tumor angiogenesis and growth in cell line xenograft models of Sutent (sunitinib)-refractory renal cell carcinoma (PMID: 26487278).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4874,
                    "therapyName": "Sunitinib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6896,
                        "pubMedId": 26487278,
                        "title": "Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26487278"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16746,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease as best response in 50% (8/16) of patients with uveal melanoma (PMID: 22805292; NCT00687622).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 6039,
                    "name": "uveal melanoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 233,
                        "pubMedId": 22805292,
                        "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805292"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10813,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Mekinist (trametinib) treatment in patients with oral cavity squamous cell carcinoma was associated with decreased phosphorylation of Erk1/2 and reduced CD44 expression, and resulted in a partial response in 65% (11/17), stable disease in 29% (5/17), and progressive disease in 1 patient (6%) (PMID: 28151720).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 50866,
                    "name": "oral squamous cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8851,
                        "pubMedId": 28151720,
                        "title": "Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151720"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11972,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, 42% (11/26) of pancreatic cancer patients demonstrated a decrease in tumor formation when treated with Mekinist (trametinib) (PMID: 22805291).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 445,
                        "pubMedId": 22805291,
                        "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805291"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2858,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Trametinib (GSK1120212) and Uprosertib (GSK2141795) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol (Meeting Abstracts) 2011 29: 3085).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1298,
                    "therapyName": "Trametinib + Uprosertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3509,
                        "pubMedId": null,
                        "title": "Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).",
                        "url": "http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/3085"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4011,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO4987655 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 22767668).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 903,
                    "therapyName": "RO4987655",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4366,
                        "pubMedId": 22767668,
                        "title": "Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22767668"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10718,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO4987655 demonstrated safety and preliminary clinical activity in Japanese patients with advanced solid tumors, including 1 partial response in a patient with esophageal cancer and 7 patients achieving progression-free survival for greater than 16 weeks (PMID: 25809858).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 903,
                    "therapyName": "RO4987655",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8783,
                        "pubMedId": 25809858,
                        "title": "Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25809858"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10457,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in complete response in 3.3% (1/30) and partial response in 6.7% (2/30) of patients with biliary tract cancer, with estimated progression free survival of 2.1 months and overall survival of 4.8 months (PMID: 28152546).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4607,
                    "name": "biliary tract cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8465,
                        "pubMedId": 28152546,
                        "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 736,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in complete response in 1% (1/91), partial response in 2% (2/91), and stable disease with median duration of 3.94 months in 36% (33/91) of patients with advanced solid tumors (PMID: 28152546).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8465,
                        "pubMedId": 28152546,
                        "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7047,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, the combination of Binimetinib (MEK162) and FOLFOX chemotherapy demonstrated manageable toxicity and preliminary efficacy in metastatic colorectal cancer patients with chemotherapy resistance (J Clin Oncol 34, 2016 (suppl; abstr 2544)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2217,
                    "therapyName": "Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Binimetinib  + FOLFOX"
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6053,
                        "pubMedId": null,
                        "title": "A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.",
                        "url": "http://meetinglibrary.asco.org/content/162654-176"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16186,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, combination therapy with Taxol (paclitaxel) and Mektovi (binimetinib) was tolerable and resulted in an objective response rate of 18% (5/28, 1 complete response, 4 partial responses) and a clinical benefit rate of 57% (16/28, best overall response of stable disease or better) in patients with platinum resistant/refractory epithelial ovarian cancer, and clinical benefit was observed in all patients with MAPK pathway alterations (n=4) (PMID: 29844129; NCT01649336).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2010,
                    "therapyName": "Binimetinib + Paclitaxel",
                    "synonyms": null
                },
                "indication": {
                    "id": 2152,
                    "name": "ovary epithelial cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 14290,
                        "pubMedId": 29844129,
                        "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2063,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Selumetinib (AZD6244) and AZD8055 worked synergistically to inhibit tumor growth in xenograft models of rhabdomyosarcoma (PMID: 23918606).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2561,
                    "therapyName": "AZD8055 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3247,
                    "name": "rhabdomyosarcoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2538,
                        "pubMedId": 23918606,
                        "title": "Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23918606"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10478,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Selumetinib (AZD6244) and Deticene (dacarbazine) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with partial responses in 17% (4/23) and stable disease for greater than 6 weeks in 65% (15/23) of patients (PMID: 28264648).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1432,
                    "therapyName": "Dacarbazine + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8532,
                        "pubMedId": 28264648,
                        "title": "A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28264648"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10477,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the combination of Selumetinib (AZD6244) and Taxotere (docetaxel) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with partial responses in 22% (6/27) and stable disease for greater than 6 weeks in 52% (14/27) of patients (PMID: 28264648).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1117,
                    "therapyName": "Docetaxel + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8532,
                        "pubMedId": 28264648,
                        "title": "A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28264648"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3762,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of KW-2450 and Selumetinib worked synergistically to inhibit growth of triple-negative breast cancer cells in culture (PMID: 26443806).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3295,
                    "therapyName": "KW-2450 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4114,
                        "pubMedId": 26443806,
                        "title": "Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26443806"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10481,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, the combination of Selumetinib (AZD6244) and MK2206 did not result in improved median overall survival compared to mFOLFOX therapy (3.9 mo vs. 6.7 mo) or improved median progression-free survival (1.9 mo vs 2.0 mo) in patients with pancreatic adenocarcinoma (PMID: 27978579).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1098,
                    "therapyName": "MK2206 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4074,
                    "name": "pancreatic adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 8534,
                        "pubMedId": 27978579,
                        "title": "Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27978579"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1150,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a meta-analysis, Selumetinib (AZD6244) was shown to have modest clinical efficacy as a monotherapy in a variety of solid tumors (PMID: 24716986).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 899,
                        "pubMedId": 24716986,
                        "title": "Efficacy and safety of selumetinib compared with current therapies for advanced cancer: a meta-analysis.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24716986"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8396,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, treatment with Selumetinib (AZD6244) demonstrated safety and preliminary efficacy patients with advanced solid tumors, with several patients achieving prolonged stable disease (PMID: 18390968).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3898,
                        "pubMedId": 18390968,
                        "title": "Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/18390968"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3619,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, treatment with Selumetinib (AZD6244) demonstrated safety and preliminary efficacy patients with advanced solid tumors, including patients with breast cancer, with several patients achieving prolonged stable disease (PMID: 18390968).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3898,
                        "pubMedId": 18390968,
                        "title": "Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/18390968"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4903,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial, Selumetinib (AZD6244) demonstrated safety and tolerability but had minimal activity with a complete response achieved in 5.6% (2/36) of refractory multiple myeloma patients (PMID: 26446942).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9538,
                    "name": "multiple myeloma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 4786,
                        "pubMedId": 26446942,
                        "title": "A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446942"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16749,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Selumetinib (AZD6244) improved median progression-free survival (15.9 vs 7 weeks, HR=0.46, p<0.001) but not overall survival (11.8 vs 9.1 months, HR=0.66, p=0.09) compared to chemotherapy in patients with uveal melanoma, but also caused high adverse event rate (PMID: 24938562; NCT01143402).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 6039,
                    "name": "uveal melanoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8678,
                        "pubMedId": 24938562,
                        "title": "Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24938562"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8533,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the Mek inhibitor Selumetinib (AZD6244) inhibited tumorigenicity and invasiveness of triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26384399).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6682,
                        "pubMedId": 26384399,
                        "title": "MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26384399"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15055,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination therapy of SHP099 and Selumetinib (AZD6244) led to decreased cell viability and reduced colony formation in triple-receptor negative breast cancer cells in culture and tumor regression in xenograft models (PMID: 30045908).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7400,
                    "therapyName": "Selumetinib + SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 12547,
                        "pubMedId": 30045908,
                        "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15056,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination therapy of Selumetinib (AZD6244) and SHP099 resulted in decreased colony formation and reduced cell viability in ovarian cancer cells in culture and  inhibition of tumor growth and reduced tumor angiogenesis in a patient-derived xenograft (PDX) model of ovarian cancer (PMID: 30045908).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7400,
                    "therapyName": "Selumetinib + SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 12547,
                        "pubMedId": 30045908,
                        "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15040,
                "approvalStatus": "Preclinical - Pdx & cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of SHP099 and Selumetinib (AZD6244) resulted in greater sensitivity compared to either agent alone in pancreatic ductal adenocarcinoma cells, demonstrating decreased cell viability and reduced colony formation in culture and decreased tumor growth in patient-derived xenograft (PDX) models (PMID: 30045908).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 7400,
                    "therapyName": "Selumetinib + SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 3498,
                    "name": "pancreatic ductal adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 12547,
                        "pubMedId": 30045908,
                        "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8713,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) and Selumetinib (AZD6244) combination treatment resulted in partial response in 15% (4/27) and stable disease in 48% (13/27) of hepatocellular carcinoma patients (PMID: 27681866).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4801,
                    "therapyName": "Selumetinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6716,
                        "pubMedId": 27681866,
                        "title": "A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681866"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2717,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, AZD8330 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors (PMID: 23433846).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 658,
                    "therapyName": "AZD8330",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3433,
                        "pubMedId": 23433846,
                        "title": "A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23433846"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4615,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with Pimasertib (MSC1936369B) followed by Gemzar (gemcitabine) resulted in enhanced inhibition of proliferation and induction of apoptosis in pancreatic cell lines in culture (PMID: 26228206).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3526,
                    "therapyName": "Gemcitabine + Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1793,
                    "name": "pancreatic cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4571,
                        "pubMedId": 26228206,
                        "title": "The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26228206"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 441,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Pimasertib in combination with Gemzar (gemcitabine) demonstrated safety and efficacy in metastatic pancreatic adenocarcinoma patients (PMID: 23846936).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3526,
                    "therapyName": "Gemcitabine + Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4074,
                    "name": "pancreatic adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 186,
                        "pubMedId": 23846936,
                        "title": "Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23846936"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4044,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Pimasertib (MSC1936369B) demonstrated safety and some preliminary anti-tumor activity in patients with advanced solid tumors (J Clin Oncol 28:15s, 2010 (suppl; abstr 2504)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 871,
                    "therapyName": "Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4385,
                        "pubMedId": null,
                        "title": "First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors",
                        "url": "http://meetinglibrary.asco.org/content/43866-74"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10475,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of SL327 and Sutent (sunitinib) worked additively to decrease viability, induce apoptosis, and decrease migration of Taxotere (docetaxel)-resistant anaplastic thyroid cancer cell lines in culture, and to inhibit tumor growth in xenograft models (PMID: 28178630)",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5526,
                    "therapyName": "SL327 + Sunitinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8529,
                        "pubMedId": 28178630,
                        "title": "Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28178630"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4019,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, TAK-733 demonstrated safety and some preliminary efficacy in patients with advanced solid tumors with partial response in 5% (2/41) and stable disease in 37% (15/41) of patients (PMID: 27650277).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 932,
                    "therapyName": "TAK-733",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4369,
                        "pubMedId": null,
                        "title": "Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.",
                        "url": "http://meetinglibrary.asco.org/content/112399-132"
                    },
                    {
                        "id": 8527,
                        "pubMedId": 27650277,
                        "title": "A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27650277"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13915,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 7% (7/84) of patients with metastatic colorectal cancer, with a median duration of response of 14.8 months, a disease control rate of 31% (26/84), a median progression-free survival of 1.9 months, and a median overall survival of 10.0 months (Journal of Clinical Oncology 36, no. 4_suppl (February 1 2018) 560-560; NCT01988896).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 11357,
                        "pubMedId": null,
                        "title": "A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).",
                        "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.560"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 14626,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (IMblaze370), Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment did not improve median overall survival (8.9 vs 8.5 months, HR=1.00, p=0.987) compared to Stivarga (regorafenib) in patients with chemotherapy-refractory metastatic colorectal cancer, 91.7% of whom were microsatellite stable or microsatellite instability-low (Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018; NCT02788279).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 11788,
                        "pubMedId": null,
                        "title": "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer",
                        "url": "https://academic.oup.com/annonc/article/29/suppl_5/mdy208.003/5043313"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1135,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) induced cell death in several human melanoma cell lines in culture and inhibited tumor growth in xenograft models (PMID: 22084396).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 353,
                        "pubMedId": 22084396,
                        "title": "Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22084396"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16569,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, and at 11.9 months the median duration of response and progression-free survival were not yet reached (PMID: 30867592; NCT01953926).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60073,
                    "name": "lymphatic system cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 14632,
                        "pubMedId": 30867592,
                        "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1839,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Cotellic (cobimetinib) treatment resulted in stable disease for five months or more in five patients with advanced solid tumors (PMID: 27424159).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2262,
                        "pubMedId": null,
                        "title": "Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors",
                        "url": "http://cancerres.aacrjournals.org/content/71/8_Supplement/4716.short"
                    },
                    {
                        "id": 10025,
                        "pubMedId": 27424159,
                        "title": "A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27424159"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1367,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial Ipatasertib (GDC-0068), in combination with the Mek inhibitor Cobimetinib (GDC-0973) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Cancer Res, October 1, 2014 74; CT328).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1160,
                    "therapyName": "Cobimetinib + Ipatasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1084,
                        "pubMedId": null,
                        "title": "Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors",
                        "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/CT328.short"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4074,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, CI-1040 treatment resulted in median stable disease for 5.5 months in 28% (19/66) of patients with advanced solid tumors (including colorectal, non-small-cell lung, pancreatic, melanoma, and kidney) and partial response in 1 pancreatic cancer patient (PMID: 16009947).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4390,
                        "pubMedId": 16009947,
                        "title": "Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/16009947"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10195,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of BI 2536 and PD-0325901 resulted in greater inhibition of cell proliferation in glioblastoma cells in culture compared to treatment with either agent alone (PMID: 26573800).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5423,
                    "therapyName": "BI2536 + PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8161,
                        "pubMedId": 26573800,
                        "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 439,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, PD-0325901 demonstrated some efficacy, however, the dose administered resulted in a significant degree of toxicity (PMID: 21516509).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 170,
                        "pubMedId": 21516509,
                        "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1129,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, PD-0325901 demonstrated some efficacy in previously treated melanoma patients, however, there was significant toxicity above 10 mg BID (PMID: 21516509).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 170,
                        "pubMedId": 21516509,
                        "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 438,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I study, PD-325901 demonstrated efficacy but toxicity at current dose was unacceptable (PMID: 21516509).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 170,
                        "pubMedId": 21516509,
                        "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1354,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, PD-0325901 demonstrated preliminary clinical activity in patients with advanced solid tumors, however late-onset dose-limiting toxicities were encountered (PMID: 20215549).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 1064,
                        "pubMedId": 20215549,
                        "title": "Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20215549"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1846,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PD-0325901, in combination with PF-04691502, delayed tumor growth in patient-derived xenograft models of bladder cancer (PMID: 24442130).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2434,
                    "therapyName": "PD-0325901 + PF-04691502",
                    "synonyms": null
                },
                "indication": {
                    "id": 11054,
                    "name": "urinary bladder cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2265,
                        "pubMedId": 24442130,
                        "title": "Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24442130"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2753,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO5126766 demonstrated safety and preliminary efficacy in patients with a variety of solid tumors (PMID: 22761467).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2011,
                    "therapyName": "RO5126766",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 3457,
                        "pubMedId": 22761467,
                        "title": "First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22761467"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10719,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, RO5126766 demonstrated safety and some preliminary activity in Japanese patients with advanced solid tumors, with 42% (5/12) of patients achieving stable disease (PMID: 23860959).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2011,
                    "therapyName": "RO5126766",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8784,
                        "pubMedId": 23860959,
                        "title": "Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23860959"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7395,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a colon cancer cell line treated with AZ628 demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4487,
                    "therapyName": "AZ628 + CPI-455",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6341,
                        "pubMedId": 27214401,
                        "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7755,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, the treatment combination of Avastin (bevacizumab) and Nexavar (sorafenib) in patients with advanced solid tumors resulted in stable disease in 25% (29/115) of patients and a partial response in 5% (6/115) of patients (PMID: 25363205).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4517,
                    "therapyName": "Bevacizumab + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6478,
                        "pubMedId": 25363205,
                        "title": "Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363205"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7562,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab) did not result in a significant improvement in progression-free survival compared to treatment with Avastin (bevacizumab) as a single agent (9.2 months vs 7.4 months) in patients with renal clear cell carcinoma (PMID: 26077237).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4517,
                    "therapyName": "Bevacizumab + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4467,
                    "name": "clear cell renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6421,
                        "pubMedId": 26077237,
                        "title": "BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26077237"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10320,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) in combination with Platinol (cisplatin) and Gemzar (gemcitabine) resulted in pathologic complete response in 42.2% (19/45) of patients with muscle-invasive urothelial bladder cancer (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5462,
                    "therapyName": "Cisplatin + Gemcitabine + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 6477,
                    "name": "invasive bladder transitional cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8305,
                        "pubMedId": null,
                        "title": "Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.",
                        "url": "http://meetinglibrary.asco.org/content/179076-197"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10797,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with the combination of CVX-060 and Nexavar (sorafenib) resulted in increased tumor growth inhibition compared to either agent alone in a colon cancer cell line xenograft model (PMID: 21233403).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 5623,
                    "therapyName": "CVX-060 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8820,
                        "pubMedId": 21233403,
                        "title": "Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21233403"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8714,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial, the combination treatment of Nexavar (sorafenib) with Tarceva (erlotinib) compared to Nexavar (sorafenib) plus placebo did not demonstrate an improved overall survival and time to progression in patients with hepatocellular carcinoma (PMID: 25547503).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4800,
                    "therapyName": "Erlotinib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6715,
                        "pubMedId": 25547503,
                        "title": "SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25547503"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5048,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Gilenya (fingolimod) worked synergistically with Nexavar (sorafenib) to inhibit growth and induce apoptosis in hepatocellular carcinoma cell lines in culture (PMID: 26516583).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3739,
                    "therapyName": "Fingolimod + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4862,
                        "pubMedId": 26516583,
                        "title": "FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26516583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1358,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Acrichine (quinacrine) and Adrucil (5-fluorouracil) synergistically enhanced the cytotoxicity of Nexavar (sorafenib) in human colorectal cancer cell lines in culture (PMID: 21725213).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4643,
                    "therapyName": "Fluorouracil + Quinacrine + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 172,
                        "pubMedId": 21725213,
                        "title": "Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725213"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 513,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Nexavar (sorafenib) in combination with Adrucil (fluorouracil) displayed safety and efficacy in advanced solid tumors, including colon cancer (PMID: 22232731).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1086,
                    "therapyName": "Fluorouracil + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 305,
                        "pubMedId": 22232731,
                        "title": "Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22232731"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 652,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Nexavar (sorafenib) in combination with Adrucil (fluorouracil) displayed safety and efficacy in advanced solid tumors, including colon cancer (PMID: 22232731).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1086,
                    "therapyName": "Fluorouracil + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 305,
                        "pubMedId": 22232731,
                        "title": "Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22232731"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6064,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of GW5074 and Nexavar (sorafenib) induced cell death in several tumor cell lines, and phosphorylation of DAPK at amino acid S308 correlated positively with response to therapy (PMID: 26100670).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3376,
                    "therapyName": "GW5074 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4259,
                        "pubMedId": 26100670,
                        "title": "Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26100670"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3877,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of GW5074 and Nexavar (sorafenib) worked synergistically to induce cell death in renal cell carcinoma cells in culture and inhibited tumor growth in xenograft and spontaneous mouse models of renal cell carcinoma (PMID: 26100670).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 3376,
                    "therapyName": "GW5074 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 4259,
                        "pubMedId": 26100670,
                        "title": "Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26100670"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7243,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, the combination of Revlimid (lenalidomide) and Nexavar (sorafenib) was not well-tolerated and did not demonstrate clinical activity in patients with hepatocellular carcinoma, and the study was terminated early due to toxicity (PMID: 27256874).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4426,
                    "therapyName": "Lenalidomide + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6255,
                        "pubMedId": 27256874,
                        "title": "Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27256874"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9341,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, addition of Glucophage (metformin) sensitized hepatocellular carcinoma cells to Nexavar (sorafenib) induced apoptosis in culture, resulted in suppression of postoperative intrahepatic recurrence and lung metastasis in cell line xenograft models (PMID: 26957312).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4982,
                    "therapyName": "Metformin + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7120,
                        "pubMedId": 26957312,
                        "title": "Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26957312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7305,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial, the combination of Alimta (pemetrexed) and Nexavar (sorafenib) demonstrated safety and some preliminary efficacy in patients with advanced solid tumors, with an objective response rate of 15% (5/33) and stable disease in 45% (15/33) of patients (PMID: 27213589).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1482,
                    "therapyName": "Pemetrexed + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6305,
                        "pubMedId": 27213589,
                        "title": "Phase I study of pemetrexed with sorafenib in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27213589"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7306,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial in patients with advanced solid tumors, the combination of Alimta (pemetrexed) and Nexavar (sorafenib) demonstrated safety and preliminary efficacy in patients with triple-receptor breast cancer (TNBC), with 60% (3/5) of TNBC patients demonstrating an objective response and 100% (5/5) of patients achieving stable disease or better (PMID: 27213589).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1482,
                    "therapyName": "Pemetrexed + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60081,
                    "name": "triple-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6305,
                        "pubMedId": 27213589,
                        "title": "Phase I study of pemetrexed with sorafenib in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27213589"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7307,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I clinical trial in patients with advanced solid tumors, the combination of Alimta (pemetrexed) and Nexavar (sorafenib) demonstrated safety and preliminary efficacy in patients with breast cancer, with 58% (7/12) of breast cancer patients achieving objective response or stable disease (PMID: 27213589).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 1482,
                    "therapyName": "Pemetrexed + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1612,
                    "name": "breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6305,
                        "pubMedId": 27213589,
                        "title": "Phase I study of pemetrexed with sorafenib in advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27213589"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 593,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with the combination of Stivarga (regorafenib) PK-866 resulted in increased cell death in a variety of solid tumor cell lines in culture (PMID: 23877009).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4494,
                    "therapyName": "PX-866 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 346,
                        "pubMedId": 23877009,
                        "title": "Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23877009"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6523,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I/II trial, the combination of Resminostat (4SC-201) and Nexavar (sorafenib) demonstrated increased efficacy compared to Resminostat (4SC-201) alone in advanced hepatocellular carcinoma patients, resulting in an improved progression-free survival rate of 62.5% vs. 12.5%, a median time to progression of 4.1 vs. 1.8 months, and an overall survival of 8.0 vs. 6.5 months (PMID: 26952006).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4135,
                    "therapyName": "Resminostat + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5684,
                        "pubMedId": 26952006,
                        "title": "Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26952006"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9224,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of SF1126 and Nexavar (sorafenib) was synergistic or additive in inhibiting proliferation of hepatocellular carcinoma cell lines in culture, and demonstrated increased efficacy in hepatocellular carcinoma cell line xenograft models compared to SF1126 alone (PMID: 23355037).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 4956,
                    "therapyName": "SF1126 + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 7040,
                        "pubMedId": 23355037,
                        "title": "An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23355037"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8610,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 13% (4/31), stable disease in 52% (16/31), a median progression-free survival of 4.9 months and an overall survivals of 9.7 months in gastrointestinal stromal tumor patients who failed prior tyrosine kinase inhibitors (PMID: 22270258).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9253,
                    "name": "gastrointestinal stromal tumor",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 6697,
                        "pubMedId": 22270258,
                        "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22270258"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10439,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case report, Nexavar (sorafenib) therapy based on in vitro efficacy testing using patient-derived tumor cells resulted in 43 months of disease-free in a patient with anaplastic thyroid carcinoma (PMID: 27379749).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3963,
                    "name": "thyroid carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8451,
                        "pubMedId": 27379749,
                        "title": "Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27379749"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1004,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a meta-analysis of 844 ERBB2 (HER2)-negative breast cancer patients, Nexavar (sorafenib) increased progression-free survival time, but not overall survival or objective response rate (PMID: 24940450).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60080,
                    "name": "Her2-receptor negative breast cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 716,
                        "pubMedId": 24940450,
                        "title": "Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24940450"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1970,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Nexavar (sorafenib) resulted in an improved median progression-free survival of 167 days in patients with renal cell carcinoma (PMID: 17189398).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2419,
                        "pubMedId": 17189398,
                        "title": "Sorafenib for the treatment of advanced renal cell carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/17189398"
                    },
                    {
                        "id": 15587,
                        "pubMedId": null,
                        "title": "Nexavar (sorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16307,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial, Nexavar (sorafenib) treatment resulted in an increased 2-year progression-free survival compared to placebo (81% vs 36%), an objective response rate of 33% (16/49; 1 complete response and 15 partial responses (PR)) compared in 20% (7/25; all PR) with placebo, and a median time to objective response of 9.6 months, compared to 13.3 months with placebo, in patients with refractory desmoid tumors (PMID: 30575484; NCT02066181).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 80366,
                    "name": "desmoid tumor",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 14419,
                        "pubMedId": 30575484,
                        "title": "Sorafenib for Advanced and Refractory Desmoid Tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30575484"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10450,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 6.3% (1/16) and stable disease in 87.5% (14/16) of patients with sporadic medullary thyroid carcinoma, with a median progression free survival of 17.9 months (PMID: 20368568).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3973,
                    "name": "thyroid medullary carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 8463,
                        "pubMedId": 20368568,
                        "title": "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20368568"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1997,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Nexavar (sorafenib) improved median progression free survival to 10.7 months in patients with unresectable hepatocellular carcinoma (PMID: 19144678).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 684,
                    "name": "hepatocellular carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2439,
                        "pubMedId": 19144678,
                        "title": "Sorafenib for the treatment of unresectable hepatocellular carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19144678"
                    },
                    {
                        "id": 15587,
                        "pubMedId": null,
                        "title": "Nexavar (sorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 591,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In preclinical studies, Nexavar (sorafenib) promoted apoptosis of endometrial carcinoma cells (PMID: 23463670).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2871,
                    "name": "endometrial carcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 344,
                        "pubMedId": 23463670,
                        "title": "Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3\u03b2-dependent protein degradation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23463670"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1990,
                "approvalStatus": "FDA approved",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Nexavar (sorafenib) improved median progression free survival to 10.8 months in metastatic differentiated thyroid cancer patients (PMID: 24768112).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 2438,
                        "pubMedId": 24768112,
                        "title": "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24768112"
                    },
                    {
                        "id": 15587,
                        "pubMedId": null,
                        "title": "Nexavar (sorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7710,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial, Nexavar (sorafenib) treatment in non-small cell lung carcinoma patients did not reach its primary endpoint, resulting in an overall survival similar to that when treated with placebo, however, did meet its secondary endpoint, demonstrating a greater progression free survival and time to progression when compared to placebo (PMID: 26743856).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6454,
                        "pubMedId": 26743856,
                        "title": "Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743856"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7560,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Nexavar (sorafenib) and Torisel (temsirolimus) did not prolong progression-free survival compared to treatment with Avastin (bevacizumab) monotherapy (7.4 months vs 7.5 months) in patients with renal clear cell carcinoma (PMID: 26077237).",
                "molecularProfile": {
                    "id": 17605,
                    "profileName": "Unknown unknown"
                },
                "therapy": {
                    "id": 2388,
                    "therapyName": "Sorafenib + Temsirolimus",
                    "synonyms": null
                },
                "indication": {
                    "id": 4467,
                    "name": "clear cell renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6421,
                        "pubMedId": 26077237,
                        "title": "BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26077237"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            }
        ]
    },
    "variantAssociatedClinicalTrials": [
        {
            "nctId": "NCT03975231",
            "title": "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02693535",
            "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03732703",
            "title": "Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8165,
                    "therapyName": "Dexamethasone + Enasidenib + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8166,
                    "therapyName": "Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8167,
                    "therapyName": "Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8168,
                    "therapyName": "Dexamethasone + Ixazomib + Pomalidomide + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 8164,
                    "therapyName": "Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 8169,
                    "therapyName": "Daratumumab + Dexamethasone + Ixazomib + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01754376",
            "title": "Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1229,
                    "therapyName": "Aldesleukin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02143050",
            "title": "Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1443,
                    "therapyName": "Dabrafenib + Metformin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01711632",
            "title": "BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02257424",
            "title": "The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02367859",
            "title": "Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01740648",
            "title": "Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1113,
                    "therapyName": "Fluorouracil + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014909",
            "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2054,
                    "therapyName": "CDX-3379",
                    "synonyms": null
                },
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 2064,
                    "therapyName": "CDX-3379 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 2061,
                    "therapyName": "CDX-3379 + Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 2062,
                    "therapyName": "CDX-3379 + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02034110",
            "title": "Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189030",
            "title": "Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7307,
                    "therapyName": "pLADD",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01721603",
            "title": "A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03839342",
            "title": "Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02465060",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 654,
                    "therapyName": "AZD4547",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 660,
                    "therapyName": "Osimertinib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 655,
                    "therapyName": "Capivasertib",
                    "synonyms": null
                },
                {
                    "id": 958,
                    "therapyName": "Defactinib",
                    "synonyms": null
                },
                {
                    "id": 765,
                    "therapyName": "GSK2636771",
                    "synonyms": null
                },
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                },
                {
                    "id": 1402,
                    "therapyName": "Ado-trastuzumab emtansine",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1016,
                    "therapyName": "Taselisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02130466",
            "title": "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1450,
                    "therapyName": "Pembrolizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1448,
                    "therapyName": "Dabrafenib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1449,
                    "therapyName": "Dabrafenib + Pembrolizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04017650",
            "title": "Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8571,
                    "therapyName": "Cetuximab + Encorafenib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01709292",
            "title": "Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03365882",
            "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1874,
                    "therapyName": "Cetuximab + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03260491",
            "title": "U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6978,
                    "therapyName": "U3-1402",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03255083",
            "title": "DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6583,
                    "therapyName": "DS-1205c + Osimertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03631706",
            "title": "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5860,
                    "therapyName": "M7824",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03973918",
            "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02949843",
            "title": "Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4918,
                    "therapyName": "Nivolumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01089101",
            "title": "Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01897116",
            "title": "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1281,
                    "therapyName": "Hydroxychloroquine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03581292",
            "title": "Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1193,
                    "therapyName": "Temozolomide + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03864042",
            "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7997,
                    "therapyName": "Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole",
                    "synonyms": null
                },
                {
                    "id": 7995,
                    "therapyName": "Modafinil",
                    "synonyms": null
                },
                {
                    "id": 7996,
                    "therapyName": "Bupropion + Rosuvastatin",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01748149",
            "title": "Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03693170",
            "title": "encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02915666",
            "title": "A Clinical Trial of Patients With Melanoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4778,
                    "therapyName": "Dabrafenib + Digoxin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01750918",
            "title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1718,
                    "therapyName": "Dabrafenib + Panitumumab",
                    "synonyms": null
                },
                {
                    "id": 1992,
                    "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1991,
                    "therapyName": "Panitumumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03668431",
            "title": "Dabrafenib + Trametinib + PDR001 In Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6023,
                    "therapyName": "Dabrafenib + Spartalizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03915951",
            "title": "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02164916",
            "title": "S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1874,
                    "therapyName": "Cetuximab + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 1331,
                    "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02928224",
            "title": "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1874,
                    "therapyName": "Cetuximab + Irinotecan",
                    "synonyms": null
                },
                {
                    "id": 2180,
                    "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "Cetuximab + FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT03224767",
            "title": "Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03639714",
            "title": "A Study of a Personalized Neoantigen Cancer Vaccine",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7679,
                    "therapyName": "GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01943422",
            "title": "Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1300,
                    "therapyName": "Interferon alpha-2b + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01726738",
            "title": "LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01876641",
            "title": "Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1259,
                    "therapyName": "Decitabine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01534897",
            "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02382549",
            "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8248,
                    "therapyName": "6MHP vaccine + Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03181100",
            "title": "Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 3049,
                    "therapyName": "Atezolizumab + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4825,
                    "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 5606,
                    "therapyName": "Atezolizumab + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01336634",
            "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01638676",
            "title": "A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1210,
                    "therapyName": "Metformin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03475004",
            "title": "Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6838,
                    "therapyName": "Bevacizumab + Binimetinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03840915",
            "title": "M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7870,
                    "therapyName": "Cisplatin + M7824 + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 7871,
                    "therapyName": "Docetaxel + M7824",
                    "synonyms": null
                },
                {
                    "id": 7872,
                    "therapyName": "Carboplatin + M7824 + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 7873,
                    "therapyName": "Cisplatin + Gemcitabine + M7824",
                    "synonyms": null
                },
                {
                    "id": 7874,
                    "therapyName": "Carboplatin + Gemcitabine + M7824",
                    "synonyms": null
                },
                {
                    "id": 7875,
                    "therapyName": "Carboplatin + M7824 + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        }
    ],
    "variantLevelEvidence": {
        "totalCount": 232,
        "variantLevelEvidences": [
            {
                "id": 12221,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6368,
                    "therapyName": "EBI-907",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10177,
                        "pubMedId": 26810733,
                        "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6681,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4234,
                    "therapyName": "Trametinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 169,
                    "name": "neuroendocrine tumor",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5733,
                        "pubMedId": 27048246,
                        "title": "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048246"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11415,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib/II trial, Encorafenib (LGX818) and Kisqali (ribociclib) combination treatment resulted in confirmed partial response in 7.1% (2/28), unconfirmed partial response in 10.7% (3/28), and stable disease in 35.7% (10/28) of patients with melanoma harboring BRAF V600E (PMID: 28351928).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1260,
                    "therapyName": "Encorafenib + Ribociclib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9298,
                        "pubMedId": 28351928,
                        "title": "Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351928"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10194,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 676,
                    "therapyName": "BI2536",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 8161,
                        "pubMedId": 26573800,
                        "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 8203,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4657,
                    "therapyName": "Pimasertib + Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7521,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4504,
                    "therapyName": "SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 6394,
                        "pubMedId": 27362227,
                        "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 10250,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing BRAF V600E in culture, while single agent inhibition had no effect (PMID: 26140595).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5443,
                    "therapyName": "PF-00477736 + PF3644022",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 8232,
                        "pubMedId": 26140595,
                        "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7861,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4599,
                    "therapyName": "Dasatinib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6508,
                        "pubMedId": 27222538,
                        "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1321,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1028,
                        "pubMedId": 24885690,
                        "title": "Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24885690"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16235,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case report, combined Tafinlar (dabrafenib) and Mekinist (trametinib) treatment of a patient with salivary duct carcinoma harboring BRAF V600E resulted in a reduction of metastatic lesions and stable disease lasting 13 months followed by disease progression (PMID: 30323086).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 50904,
                    "name": "salivary gland carcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 14375,
                        "pubMedId": 30323086,
                        "title": "First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30323086"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3341,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3124,
                    "therapyName": "S3I-201",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3755,
                        "pubMedId": 23242808,
                        "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 16571,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including 1 partial response and 3 complete responses in 4 patients with Erdheim-Chester disease harboring BRAF V600E (PMID: 30867592; NCT01953926).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 60073,
                    "name": "lymphatic system cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 14632,
                        "pubMedId": 30867592,
                        "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 706,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, 33% (26/78) of previously treated non-small cell lung carcinoma patients harboring BRAF V600E demonstrated an overall response, which included all partial responses, when treated with Tafinlar (dabrafenib) while 67% (4/6) receiving Tafinlar (dabrafenib) as a first-line treatment achieved partial responses (PMID: 27080216; NCT01336634).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6410,
                        "pubMedId": 27080216,
                        "title": "Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27080216"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12982,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5778,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "conflicting",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8547,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "conflicting",
                "references": [
                    {
                        "id": 6683,
                        "pubMedId": 27488531,
                        "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7652,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4544,
                    "therapyName": "Dabrafenib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6589,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3268,
                    "therapyName": "LY3009120",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5709,
                        "pubMedId": 26343583,
                        "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7229,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BGB-283 resulted in partial response in 1 of 2 melanoma patients harboring BRAF V600E, who remained on treatment for over 249 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4025,
                    "therapyName": "BGB-283",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6230,
                        "pubMedId": null,
                        "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                        "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8056,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4025,
                    "therapyName": "BGB-283",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5280,
                        "pubMedId": 26208524,
                        "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11041,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9035,
                        "pubMedId": null,
                        "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                        "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6437,
                "approvalStatus": "Phase III",
                "evidenceType": "Emerging",
                "efficacyEvidence": "In a post-hoc analysis of a Phase III trial, BRAF V600E mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that BRAF V600E may serve as a future prognostic biomarker in this patient population (PMID: 26768652).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1776,
                    "therapyName": "N/A",
                    "synonyms": null
                },
                "indication": {
                    "id": 234,
                    "name": "colon adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 5600,
                        "pubMedId": 26768652,
                        "title": "Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26768652"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 16193,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafinib) treatment of a patient with recurrent neuroendocrine carcinoma of the colon harboring a BRAF V600E mutation resulted in stable disease for 6 months before disease progression (PMID: 30181415).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4118,
                    "name": "colon neuroendocrine neoplasm",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 14304,
                        "pubMedId": 30181415,
                        "title": "Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30181415"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9182,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2011,
                    "therapyName": "RO5126766",
                    "synonyms": null
                },
                "indication": {
                    "id": 3969,
                    "name": "papillary thyroid carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6994,
                        "pubMedId": 27669459,
                        "title": "Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27669459"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4953,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 and Cediranib (AZD-2171) worked synergistically to inhibit cell growth and induce apoptosis in PLX4720-resistant human melanoma cell lines harboring BRAF V600E in culture and to suppress tumor growth in xenograft models (PMID: 26461489).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3698,
                    "therapyName": "Cediranib + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4807,
                        "pubMedId": 26461489,
                        "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 17520,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Zelboraf (vemurafenib) treatment resulted in tumor regression as confirmed by MRI after 3-weeks of treatment in a patient with epithelioid glioblastoma harboring BRAF V600E (PMID: 31217909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 15565,
                        "pubMedId": 31217909,
                        "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10191,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 8161,
                        "pubMedId": 26573800,
                        "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11939,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 28649441).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9924,
                        "pubMedId": 28649441,
                        "title": "Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28649441"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8198,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1659,
                    "therapyName": "Pimasertib + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 442,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF V600E splice variants (PMID: 24422853).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1041,
                    "therapyName": "PLX8394",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 195,
                        "pubMedId": 24422853,
                        "title": "Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24422853"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12623,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 884,
                    "therapyName": "RAF265",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 10503,
                        "pubMedId": 28719152,
                        "title": "A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28719152"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4985,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3712,
                    "therapyName": "Afatinib + BI 882370",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4823,
                        "pubMedId": 26916115,
                        "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13022,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6709,
                    "therapyName": "Irinotecan + Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7649,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3783,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3308,
                    "therapyName": "BI-69A11",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4137,
                        "pubMedId": 26603897,
                        "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                    },
                    {
                        "id": 4139,
                        "pubMedId": 20531415,
                        "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 6674,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4232,
                    "therapyName": "DETD-35 + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5730,
                        "pubMedId": 27048951,
                        "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7838,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 6508,
                        "pubMedId": 27222538,
                        "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7647,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4525,
                    "therapyName": "Cetuximab + Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12695,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a partial response in two patients with lung cancer each harboring BRAF V600E (PMID: 29247021).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1324,
                    "name": "lung cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10607,
                        "pubMedId": 29247021,
                        "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 17026,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4541,
                    "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1121,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 180,
                        "pubMedId": 23414587,
                        "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7856,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6508,
                        "pubMedId": 27222538,
                        "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10196,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of BI 2536 and PLX4720 resulted in suppression of downstream signaling, increased apoptotic activity, inhibition of cell proliferation, and tumor growth suppression in glioblastoma cell line xenograft models harboring BRAF V600E (PMID: 26573800).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5422,
                    "therapyName": "BI2536 + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 8161,
                        "pubMedId": 26573800,
                        "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7653,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4542,
                    "therapyName": "Cetuximab + Dabrafenib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12170,
                "approvalStatus": "Guideline",
                "evidenceType": "Diagnostic",
                "efficacyEvidence": "BRAF V600E is diagnostic and aids distinguishing classic hairy cell leukemia (HCL-C) from variant hairy cell leukemia (HCL-V) and other B-cell lymphomas and leukemias (PMID: 29118233).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1776,
                    "therapyName": "N/A",
                    "synonyms": null
                },
                "indication": {
                    "id": 285,
                    "name": "hairy cell leukemia",
                    "source": "DOID"
                },
                "responseType": "not applicable",
                "references": [
                    {
                        "id": 10462,
                        "pubMedId": 29118233,
                        "title": "Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29118233"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 17521,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with epithelioid glioblastoma harboring BRAF V600E continued to response as Cotellic (cobimetinib) was added to Zelboraf (vemurafenib) treatment (PMID: 31217909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 15565,
                        "pubMedId": 31217909,
                        "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4525,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3530,
                    "therapyName": "Navitoclax + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5985,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3027,
                    "therapyName": "GSK2126458 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7515,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4504,
                    "therapyName": "SHP099",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6394,
                        "pubMedId": 27362227,
                        "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 9106,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and Afinitor (everolimus) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4901,
                    "therapyName": "Everolimus + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3070,
                    "name": "malignant glioma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 6921,
                        "pubMedId": 27217440,
                        "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12838,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 468,
                        "pubMedId": 22663011,
                        "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15457,
                        "pubMedId": null,
                        "title": "Mekinist (trametinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 586,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (BRIM-3) that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival (OS) (13.6 vs 9.7 months, HR=0.81, p=0.03) in patients with BRAF V600E-positive metastatic melanoma, with estimated OS rates of 56%, 30%, 21%, and 17% at 1, 2, 3, and 4 years, respectively (PMID: 28961848, PMID: 21639808; NCT01006980), and BRAF V600E is included on the companion diagnostic (FDA.gov).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 222,
                        "pubMedId": 21639808,
                        "title": "Improved survival with vemurafenib in melanoma with BRAF V600E mutation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21639808"
                    },
                    {
                        "id": 11411,
                        "pubMedId": 28961848,
                        "title": "Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961848"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15452,
                        "pubMedId": null,
                        "title": "Zelboraf (vemurafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202429"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1510,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7906,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1093,
                    "therapyName": "AZ628",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6522,
                        "pubMedId": 27523909,
                        "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1325,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Zelboraf (vemurafenib) and Tarceva (erlotinib) resulted in improved inhibition of tumor growth in BRAF V600E mutant human colon cancer cell line xenograft models compared to either drug as monotherapy (PMID: 22448344).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1710,
                    "therapyName": "Erlotinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1032,
                        "pubMedId": 22448344,
                        "title": "EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22448344"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7936,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3300,
                    "therapyName": "TAK-632",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6522,
                        "pubMedId": 27523909,
                        "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8057,
                "approvalStatus": "Preclinical - Pdx & cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in colorectal cancer cell lines harboring BRAF V600E in culture, and resulted in partial tumor regression in both cell line and patient-derived xenograft models (PMID: 26208524).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4025,
                    "therapyName": "BGB-283",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5280,
                        "pubMedId": 26208524,
                        "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4534,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3531,
                    "therapyName": "TW-37 + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1323,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1708,
                    "therapyName": "Lapatinib + Panobinostat",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1031,
                        "pubMedId": 21464044,
                        "title": "The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21464044"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 17589,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a papillary thyroid carcinoma patient who progressed on Lenvima (lenvatinib) was found to harbor BRAF V600E and was treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) on a clinical trial, resulting in partial response in the thyroid bed, cervical and intrathoracic lymph nodes, and pulmonary lesions, with a decrease in target lesion size of 67%, and the patient remained on treatment for 18 months before stopping due to progression (PMID: 31085763).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3969,
                    "name": "papillary thyroid carcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 15690,
                        "pubMedId": 31085763,
                        "title": "KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085763"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5648,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with metastatic renal cell carcinoma harboring BRAF V600E demonstrated a partial response following treatment with Zelboraf (vemurafenib) (PMID: 26918217).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4450,
                    "name": "renal cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5134,
                        "pubMedId": 26918217,
                        "title": "A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26918217"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4528,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1386,
                    "therapyName": "Navitoclax + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5779,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5780,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3769,
                    "therapyName": "DEL-22379",
                    "synonyms": null
                },
                "indication": {
                    "id": 50861,
                    "name": "colorectal adenocarcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 17028,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 8361,
                    "therapyName": "Binimetinib + Encorafenib + Panitumumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9107,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1061,
                    "therapyName": "PLX4720 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3070,
                    "name": "malignant glioma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 6921,
                        "pubMedId": 27217440,
                        "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8549,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in significant tumor regression in melanoma cell line xenograft models harboring BRAF V600E and demonstrated a 56% (5/9) complete response rate (PMID: 27488531).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1823,
                    "therapyName": "Palbociclib + PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6683,
                        "pubMedId": 27488531,
                        "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 306,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 203,
                        "pubMedId": 22319199,
                        "title": "CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22319199"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4986,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3709,
                    "therapyName": "BI 882370 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4823,
                        "pubMedId": 26916115,
                        "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7651,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4543,
                    "therapyName": "Cetuximab + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 6680,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 169,
                    "name": "neuroendocrine tumor",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 5733,
                        "pubMedId": 27048246,
                        "title": "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048246"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1322,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Tykerb (lapatinib) and Zelboraf (vemurafenib) inhibited growth of thyroid cancer cells harboring a BRAF V600E mutation in culture and in BRAF-mutant mouse models of thyroid cancer (PMID: 23365119).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1707,
                    "therapyName": "Lapatinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1029,
                        "pubMedId": 23365119,
                        "title": "Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23365119"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12222,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of colorectal cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6368,
                    "therapyName": "EBI-907",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10177,
                        "pubMedId": 26810733,
                        "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3334,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3131,
                    "therapyName": "Gefitinib + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3755,
                        "pubMedId": 23242808,
                        "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5970,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 763,
                    "therapyName": "GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 1849,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1717,
                    "therapyName": "Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2277,
                        "pubMedId": 25589621,
                        "title": "Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25589621"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15706,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in colorectal cancer cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 11466,
                        "pubMedId": 28939558,
                        "title": "Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939558"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 6827,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SB590885 inhibited inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4281,
                    "therapyName": "SB590885",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16105,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 50% (2/4, 2 partial response) in patients with ovarian cancer harboring BRAF V600E, and stable disease lasting more than 120 days in 1 patient (PMID: 29320312; NCT02091141).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 13171,
                        "pubMedId": 29320312,
                        "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8066,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB-283 inhibited viability of a variety of cancer cell lines harboring BRAF V600E in culture (PMID: 26208524).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4025,
                    "therapyName": "BGB-283",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5280,
                        "pubMedId": 26208524,
                        "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7615,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11927,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 9911,
                        "pubMedId": 22281684,
                        "title": "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22281684"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9421,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate meaningful clinical activity as a single agent, resulted in partial response in 5% (1/21) and stable disease in 33% (7/21) of patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303; NCT00405587).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 7183,
                        "pubMedId": 26460303,
                        "title": "Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26460303"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8188,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 871,
                    "therapyName": "Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1130,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 888,
                    "therapyName": "Refametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 877,
                        "pubMedId": 19706763,
                        "title": "RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19706763"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9665,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Tarceva (erlotinib) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models and culture (PMID: 27924459).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5120,
                    "therapyName": "Erlotinib + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 7369,
                        "pubMedId": 27924459,
                        "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4954,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1061,
                    "therapyName": "PLX4720 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4807,
                        "pubMedId": 26461489,
                        "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9947,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Erbitux (cetuximab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 8548,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 6683,
                        "pubMedId": 27488531,
                        "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 6673,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4230,
                    "therapyName": "DETD-35",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5730,
                        "pubMedId": 27048951,
                        "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5564,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3769,
                    "therapyName": "DEL-22379",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 5776,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2618,
                    "therapyName": "SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 15904,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial (VE-BASKET), Zelboraf (vemurafenib) treatment of BRAF V600E mutant pleomorphic xanthoastrocytomas resulted in a 42.9% (3/7) objective response rate, a 5.7-month median progression-free survival, and best overall response rates of 14.3% (1/7) for complete response, 28.6% (2/7) for partial response, and 42.9% (3/7) for stable disease (PMID: 30351999; NCT01524978).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4852,
                    "name": "pleomorphic xanthoastrocytoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 13949,
                        "pubMedId": 30351999,
                        "title": "BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30351999"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7966,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4607,
                    "therapyName": "PLX4720 + TAK-632",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6522,
                        "pubMedId": 27523909,
                        "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12998,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1331,
                    "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4955,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3699,
                    "therapyName": "Cediranib + PLX4720 + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4807,
                        "pubMedId": 26461489,
                        "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15903,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II clinical trial (VE-BASKET), treatment of patients with gliomas harboring BRAF V600E mutations with Zelboraf (vemurafenib) resulted in a 25% (6/24) objective response rate, 5.5-month median progression free survival, 28.2 month median overall survival, and best overall response rates of 4.2% (1/24) for complete response, 20.8% (5/24) for partial response, and 41.7% (10/24) for stable disease (PMID: 30351999; NCT01524978).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3070,
                    "name": "malignant glioma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 13949,
                        "pubMedId": 30351999,
                        "title": "BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30351999"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 17025,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1992,
                    "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8193,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4656,
                    "therapyName": "Everolimus + Pimasertib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 337,
                        "pubMedId": 23629727,
                        "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1319,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1025,
                        "pubMedId": 25309914,
                        "title": "Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25309914"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16978,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4541,
                    "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12192,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, LSN3074753 demonstrated modest efficacy in patient-derived xenograft models of colorectal cancer harboring BRAF V600E, resulted in tumor growth inhibition or regression, but relapse upon discontinuation of treatment (PMID: 28611205).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6337,
                    "therapyName": "LSN3074753",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 10143,
                        "pubMedId": 28611205,
                        "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4526,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3530,
                    "therapyName": "Navitoclax + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3785,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3307,
                    "therapyName": "SBI-0640726",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4137,
                        "pubMedId": 26603897,
                        "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                    },
                    {
                        "id": 4139,
                        "pubMedId": 20531415,
                        "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7650,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4541,
                    "therapyName": "Cetuximab + Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7946,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4281,
                    "therapyName": "SB590885",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6522,
                        "pubMedId": 27523909,
                        "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7900,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4606,
                    "therapyName": "PLX7904",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6521,
                        "pubMedId": 26466569,
                        "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26466569"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9664,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Adriamycin (doxorubicin) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and inhibition of cell growth in culture (PMID: 27924459).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5122,
                    "therapyName": "Doxorubicin + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 7369,
                        "pubMedId": 27924459,
                        "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1131,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 228,
                        "pubMedId": 22048237,
                        "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13889,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib), Vectibix (panitumumab), and Mekinist (trametinib) resulted in an overall response rate of 21% (19/91, 1 complete response, 18 partial response), stable disease in 65% (59/91), and a median progression-free survival of 4.2 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1992,
                    "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 11333,
                        "pubMedId": 29431699,
                        "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1312,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 318,
                        "pubMedId": 21170960,
                        "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8069,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4628,
                    "therapyName": "BGB-283 + Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5280,
                        "pubMedId": 26208524,
                        "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7618,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4536,
                    "therapyName": "Cetuximab + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8711,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case report, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 80522,
                    "name": "thyroid gland anaplastic carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6714,
                        "pubMedId": 27697975,
                        "title": "Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697975"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12685,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial (ROAR) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an overall response rate of 69% (11/16; 1 complete response and 10 partial responses) in patients with anaplastic thyroid cancer harboring BRAF V600E (PMID: 29072975; NCT02034110).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 80522,
                    "name": "thyroid gland anaplastic carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10600,
                        "pubMedId": 29072975,
                        "title": "Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29072975"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15458,
                        "pubMedId": null,
                        "title": "Tafinlar (dabrafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3784,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3306,
                    "therapyName": "SBI-0640756",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4137,
                        "pubMedId": 26603897,
                        "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                    },
                    {
                        "id": 4139,
                        "pubMedId": 20531415,
                        "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 3620,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In two Phase II clinical studies, patients with refractory hairy cell leukemia harboring BRAF V600E responded to Zelboraf (vemurafenib) with overall response rates of 96% (25/26) and 100% (24/24) as well as complete response rates of 35% (9/26) and 42% (10/24) with median follow up times of 8 and 12 weeks, respectively (PMID: 26352686).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 285,
                    "name": "hairy cell leukemia",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3911,
                        "pubMedId": 26352686,
                        "title": "Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26352686"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9662,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Alpelisib (BYL719) and PLX4720 enhanced antitumor activity in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Akt signaling in culture (PMID: 27924459).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5119,
                    "therapyName": "Alpelisib + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 7369,
                        "pubMedId": 27924459,
                        "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4956,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3700,
                    "therapyName": "PLX4720 + Tivozanib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4807,
                        "pubMedId": 26461489,
                        "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13020,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Vectibix (panitumumab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 692,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3905,
                    "name": "lung carcinoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 423,
                        "pubMedId": 22649091,
                        "title": "Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22649091"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 16950,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Braftovi (encorafenib) in combination with Mektovi (binimetinib) is included in guidelines as first-line and second-line therapy for patients with metastatic or unresectable melanoma harboring BRAF V600E or V600K mutations (PMID: 30959471; NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    },
                    {
                        "id": 15109,
                        "pubMedId": 30959471,
                        "title": "Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30959471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16952,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 14457,
                        "pubMedId": 30219628,
                        "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15455,
                        "pubMedId": null,
                        "title": "Braftovi (encorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                    },
                    {
                        "id": 15456,
                        "pubMedId": null,
                        "title": "Mektovi (binimetinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16953,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453), and both BRAF V600E and V600K are on the companion diagnostic.",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 11562,
                        "pubMedId": 29573941,
                        "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15455,
                        "pubMedId": null,
                        "title": "Braftovi (encorafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                    },
                    {
                        "id": 15456,
                        "pubMedId": null,
                        "title": "Mektovi (binimetinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4984,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3711,
                    "therapyName": "BI 882370 + Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4823,
                        "pubMedId": 26916115,
                        "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16107,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in complete response in a patient with larynx cancer harboring BRAF V600E (PMID: 29320312; NCT02091141).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 2596,
                    "name": "larynx cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 13171,
                        "pubMedId": 29320312,
                        "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 14352,
                "approvalStatus": "Phase III",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III (BEACON CRC) trial, Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab) combination treatment resulted in an objective response rate of 48% (14/29, 3 complete responses), and stable disease in 52% (15/29) of patients with BRAF V600E metastatic colorectal cancer, with a median progression-free survival of 8.0 months, and a median overall survival of 15.3 months (PMID: 30892987; NCT02928224).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 15302,
                        "pubMedId": 30892987,
                        "title": "Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30892987"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 509,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 294,
                        "pubMedId": 22394203,
                        "title": "Sorafenib in melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22394203"
                    },
                    {
                        "id": 3156,
                        "pubMedId": 16880785,
                        "title": "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/16880785"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3130,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1040,
                    "therapyName": "Gedatolisib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 220,
                        "pubMedId": 21325073,
                        "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                    },
                    {
                        "id": 3639,
                        "pubMedId": 24042735,
                        "title": "Epigenetic and genetic features of 24 colon cancer cell lines.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24042735"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 4531,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3532,
                    "therapyName": "Trametinib + TW-37",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16104,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 43% (6/14, 1 complete response, 5 partial response) in patients with non-small cell lung cancer harboring BRAF V600E, and stable disease lasting more than 120 days in 2 patients (PMID: 29320312; NCT02091141).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 13171,
                        "pubMedId": 29320312,
                        "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12983,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 705,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1011,
                        "pubMedId": 23733758,
                        "title": "Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23733758"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12058,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, INU-152 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture, and reduced tumor growth in BRAF V600E-mutant colorectal cancer cell line xenograft models (PMID: 28645859).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6241,
                    "therapyName": "INU-152",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9993,
                        "pubMedId": 28645859,
                        "title": "Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645859"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12269,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10226,
                        "pubMedId": 27480103,
                        "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15453,
                        "pubMedId": null,
                        "title": "Cotellic (cobimetinib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 17034,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4028,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1011,
                    "therapyName": "E6201",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4380,
                        "pubMedId": 24448821,
                        "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3789,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3309,
                    "therapyName": "SBI-755199",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4137,
                        "pubMedId": 26603897,
                        "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 9944,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Vectibix (panitumumab), as a monotherapy, is not indicated for use in colon cancer patients with BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 845,
                    "therapyName": "Panitumumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 1341,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Encorafenib (LGX818) showed activity in patients with advanced metastatic colorectal cancer harboring a BRAF V600E mutation, resulting in a median progression-free survival of 4 months and a best response of stable disease in 66.7% (12/18) (Ann Oncol (2014) 25 (suppl 4): iv182-iv183).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1050,
                        "pubMedId": null,
                        "title": "53P Encorafenib (LGX818), an oral BRAF inhibitor, in patients (PTS) WITH BRAF V600E metastatic colorectal cancer (MCRC): results of dose expansion in an open-label, phase I study.",
                        "url": null
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16977,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib), Mekinist (trametinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1992,
                    "therapyName": "Dabrafenib + Panitumumab + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7863,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4601,
                    "therapyName": "Dasatinib + SCH772984",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6508,
                        "pubMedId": 27222538,
                        "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 4529,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1386,
                    "therapyName": "Navitoclax + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7873,
                "approvalStatus": "Preclinical - Pdx & cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BRAF V600E in cell culture, cell line xenograft and patient-derived xenograft (PDX) models (PMID: 19276360).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1095,
                    "therapyName": "GDC0879",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6516,
                        "pubMedId": 19276360,
                        "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 17519,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in significant clinical improvement in a patient with epithelioid glioblastoma harboring BRAF V600E, however, her disease progressed after 3 months of therapy (PMID: 31217909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 15565,
                        "pubMedId": 31217909,
                        "title": "Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/31217909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 14004,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, an epithelioid glioblastoma patient harboring BRAF V600E treated with Mekinist (trametinib) and Tafinlar (dabrafenib) combination therapy resulted in stable disease, and the patient continued to demonstrate stable disease at least 16 months after initiation of therapy (PMID: 29632053).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 11407,
                        "pubMedId": 29632053,
                        "title": "Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29632053"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16979,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6180,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, DT01 increased sensitivity of human colorectal cancer (CRC) cells harboring BRAF V600E to Eloxatin (oxaliplatin) and Adrucil (5-fluorouracil), and the combination resulted in decreased liver tumor growth in CRC cell line xenograft metastasis models (PMID: 26637369).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4083,
                    "therapyName": "DT01 + Fluorouracil + Oxaliplatin",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5384,
                        "pubMedId": 26637369,
                        "title": "The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637369"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 3336,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 912,
                    "therapyName": "Saracatinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3755,
                        "pubMedId": 23242808,
                        "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 1507,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, such as BRAF V600E, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 554,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III clinical trial (BREAK-3) that supported FDA approval, Tafinlar (dabrafenib) improved median progression-free survival compared to Deticene (dacarbazine) (5.1 vs 2.7 months, HR=0.3, p<0.0001) in patients with BRAF V600E positive melanoma (PMID: 22735384; NCT01227889).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 232,
                        "pubMedId": 22735384,
                        "title": "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22735384"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15458,
                        "pubMedId": null,
                        "title": "Tafinlar (dabrafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16194,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In Phase II trial, Mektovi (binimetinib) therapy in a patient with recurrent neuroendocrine carcinoma of the colon harboring a BRAF V600E mutation who had previously progressed on Tafinlar (dabrafinib) resulted in disease progression after two cycles (PMID: 30181415; NCT01885195).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4118,
                    "name": "colon neuroendocrine neoplasm",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 14304,
                        "pubMedId": 30181415,
                        "title": "Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30181415"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8461,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 903,
                    "therapyName": "RO4987655",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4382,
                        "pubMedId": 26438159,
                        "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3310,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CCT196969 inhibited growth of BRAF-mutant colorectal cancer cell lines in culture (PMID: 25500121), which have been reported to harbor BRAF V600E (PMID: 15294323).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3105,
                    "therapyName": "CCT196969",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3714,
                        "pubMedId": 25500121,
                        "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                    },
                    {
                        "id": 3729,
                        "pubMedId": 15294323,
                        "title": "Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/15294323"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4527,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1386,
                    "therapyName": "Navitoclax + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13890,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Vectibix (panitumumab) and Mekinist (trametinib) resulted in an overall response rate of 0% (0/31), stable disease in 55% (17/31), and a median progression-free survival of 2.6 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1991,
                    "therapyName": "Panitumumab + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "no benefit",
                "references": [
                    {
                        "id": 11333,
                        "pubMedId": 29431699,
                        "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11710,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a near complete response and resolution of leptomeningeal dissemination in a patient with pilocytic astrocytoma harboring BRAF V600E (PMID: 28784858).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4851,
                    "name": "pilocytic astrocytoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 9723,
                        "pubMedId": 28784858,
                        "title": "Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28784858"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5986,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4004,
                    "therapyName": "Dabrafenib + GSK2126458",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12087,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, Cotellic (cobimetinib) treatment resulted in a confirmed partial response in six melanoma patients harboring BRAF V600E (PMID: 27424159).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10025,
                        "pubMedId": 27424159,
                        "title": "A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27424159"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8478,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2011,
                    "therapyName": "RO5126766",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4382,
                        "pubMedId": 26438159,
                        "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2614,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 2960,
                    "therapyName": "Navitoclax + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3334,
                        "pubMedId": 24983357,
                        "title": "Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24983357"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3306,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3105,
                    "therapyName": "CCT196969",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3714,
                        "pubMedId": 25500121,
                        "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3311,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3106,
                    "therapyName": "CCT241161",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3714,
                        "pubMedId": 25500121,
                        "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                    },
                    {
                        "id": 3729,
                        "pubMedId": 15294323,
                        "title": "Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/15294323"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7231,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, BGB-283 resulted in partial response in 1 thyroid cancer patient harboring BRAF V600E, who remained on treatment for over 481 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4025,
                    "therapyName": "BGB-283",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6230,
                        "pubMedId": null,
                        "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                        "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12698,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (Ulixertinib) resulted in a partial response in a patient with glioblastoma harboring BRAF V600E (PMID: 29247021).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10607,
                        "pubMedId": 29247021,
                        "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 1267,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1684,
                    "therapyName": "Ganetespib + TAK-733",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 249,
                        "pubMedId": 24398428,
                        "title": "Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398428"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4981,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3709,
                    "therapyName": "BI 882370 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4823,
                        "pubMedId": 26916115,
                        "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 17027,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Erbitux (cetuximab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4886,
                    "therapyName": "Binimetinib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9660,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Gleevec (imatinib) and PLX4720 enhanced antitumor efficacy of melanoma cells harboring BRAF V600E, demonstrating decreased cell survival in xenograft models, and decreased phosphorylation of Mapk1 in culture (PMID: 27924459).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5118,
                    "therapyName": "Imatinib + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 7369,
                        "pubMedId": 27924459,
                        "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13019,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Erbitux (cetuximab), as a monotherapy, is not indicated for use in rectum cancer patients with BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 7646,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1916,
                    "therapyName": "Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7943,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3300,
                    "therapyName": "TAK-632",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6522,
                        "pubMedId": 27523909,
                        "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13021,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib), Erbitux (cetuximab), and Camptosar (irinotecan) combination therapy is included in guidelines for advanced or metastatic rectum cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1331,
                    "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1993,
                    "name": "rectum cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16106,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in complete response in a patient with anaplastic thyroid cancer harboring BRAF V600E (PMID: 29320312; NCT02091141).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "conflicting",
                "references": [
                    {
                        "id": 13171,
                        "pubMedId": 29320312,
                        "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7959,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, thyroid cancer cells harboring BRAF V600E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "conflicting",
                "references": [
                    {
                        "id": 6522,
                        "pubMedId": 27523909,
                        "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4533,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3531,
                    "therapyName": "TW-37 + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 8002,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 291,
                        "pubMedId": 18287029,
                        "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4530,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3532,
                    "therapyName": "Trametinib + TW-37",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6844,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10192,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PLX4720, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 3068,
                    "name": "glioblastoma multiforme",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 8161,
                        "pubMedId": 26573800,
                        "title": "Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26573800"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2528,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3253,
                        "pubMedId": 23942066,
                        "title": "Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23942066"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15174,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafenib) treatment resulted in partial response 8 weeks after therapy initiation in a pediatric patient with anaplastic ganglioglioma harboring BRAF V600E, but disease progression occurred at 40 weeks due to acquired resistance (PMID: 29880583).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 5078,
                    "name": "ganglioglioma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 12771,
                        "pubMedId": 29880583,
                        "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1320,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1028,
                        "pubMedId": 24885690,
                        "title": "Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24885690"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12292,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable inhibition of Erk signaling and proliferation of melanoma cells overexpressing BRAF V600E in culture (PMID: 28714990).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6430,
                    "therapyName": "Dabrafenib + SCH772984 + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 10283,
                        "pubMedId": 28714990,
                        "title": "An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28714990"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 503,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 291,
                        "pubMedId": 18287029,
                        "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11930,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, a patient with metastatic colon cancer harboring BRAF V600E demonstrated mixed radiographic response with slight progression in some locations and stable disease in other locations for 7 months following treatment with the combination of Nexavar (sorafenib) and Erbitux (cetuximab) (PMID: 23792568).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6209,
                    "therapyName": "Cetuximab + Sorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 9915,
                        "pubMedId": 23792568,
                        "title": "Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23792568"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12926,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, such as BRAF V600E, as adjuvant therapy for stage III disease and as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5987,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2092,
                        "pubMedId": 22389471,
                        "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 10549,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial, BRAF V600E positive melanoma patients who progressed on treatment with BRAF inhibitors or the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) were treated again with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) after 12 weeks off treatment, which resulted in a partial response in 35% (8/25) and stable disease in 40% (10/25) (PMID: 28268064).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 8631,
                        "pubMedId": 28268064,
                        "title": "Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28268064"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12837,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10781,
                        "pubMedId": 25399551,
                        "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15458,
                        "pubMedId": null,
                        "title": "Tafinlar (dabrafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3307,
                "approvalStatus": "Preclinical - Pdx",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3106,
                    "therapyName": "CCT241161",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3714,
                        "pubMedId": 25500121,
                        "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 2742,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 699,
                    "therapyName": "CI-1040",
                    "synonyms": null
                },
                "indication": {
                    "id": 2394,
                    "name": "ovarian cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3448,
                        "pubMedId": 19018267,
                        "title": "KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19018267"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6836,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX4720 inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1060,
                    "therapyName": "PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 14046,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 29343524).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6995,
                    "therapyName": "RAF709",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 11434,
                        "pubMedId": 29343524,
                        "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12057,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, INU-152 reduced MEK and ERK phosphorylation and growth of a melanona cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 28645859).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6241,
                    "therapyName": "INU-152",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9993,
                        "pubMedId": 28645859,
                        "title": "Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645859"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15736,
                "approvalStatus": "Clinical Study - Cohort",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival  (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 13705,
                        "pubMedId": 30630828,
                        "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 1324,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1709,
                    "therapyName": "Gefitinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1032,
                        "pubMedId": 22448344,
                        "title": "EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22448344"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1782,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 2074,
                        "pubMedId": 16273091,
                        "title": "BRAF mutation predicts sensitivity to MEK inhibition.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/16273091"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13000,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Zelboraf (vemurafenib), Vectibix (panitumumab), and Irinotecan combination therapy is included in guidelines for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6709,
                    "therapyName": "Irinotecan + Panitumumab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 745,
                    "therapyName": "Ganetespib",
                    "synonyms": null
                },
                "indication": {
                    "id": 8923,
                    "name": "skin melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 249,
                        "pubMedId": 24398428,
                        "title": "Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398428"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 4417,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3502,
                    "therapyName": "CLM3",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4527,
                        "pubMedId": 24423321,
                        "title": "CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24423321"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 3790,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) in combination with SBI-0640756 inhibited the association of eIF4G1 and eIF4E in Zelboraf (vemurafenib) resistant human melanoma cell lines harboring BRAF V600E in culture and reduced tumor growth in xenograft models (PMID: 26603897).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3310,
                    "therapyName": "SBI-0640756 + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4137,
                        "pubMedId": 26603897,
                        "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7944,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of thyroid cancer cells harboring BRAF V600E in culture (PMID: 27523909).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3300,
                    "therapyName": "TAK-632",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6522,
                        "pubMedId": 27523909,
                        "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7648,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1917,
                    "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 13891,
                "approvalStatus": "Phase I",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase I trial, combination therapy consisting of Tafinlar (dabrafenib) and Vectibix (panitumumab) resulted in an overall response rate of 10% (2/20, 1 complete response, 1 partial response), stable disease in 80% (16/20), and a median progression-free survival of 3.5 months in patients with BRAF V600E colorectal cancer (PMID: 29431699; NCT01750918).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1718,
                    "therapyName": "Dabrafenib + Panitumumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 11333,
                        "pubMedId": 29431699,
                        "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29431699"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1345,
                "approvalStatus": "Phase Ib/II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase Ib/II trial, treatment with the combination of Vectibix (panitumumab) and Tafinlar (dabrafenib) resulted in stable disease in 7/8 colorectal cancer patients harboring a BRAF V600E mutation (J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1718,
                    "therapyName": "Dabrafenib + Panitumumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1051,
                        "pubMedId": null,
                        "title": "Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).",
                        "url": "http://meetinglibrary.asco.org/content/131642-144"
                    }
                ],
                "ampCapAscoEvidenceLevel": "C",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 5777,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 849,
                    "therapyName": "PD-0325901",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4897,
                        "pubMedId": 26267534,
                        "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11929,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Erbitux (cetuximab) inhibited tumor growth in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 22281684).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 6208,
                    "therapyName": "Cetuximab + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 9911,
                        "pubMedId": 22281684,
                        "title": "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22281684"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15705,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in melanoma cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 11466,
                        "pubMedId": 28939558,
                        "title": "Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939558"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 14003,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in clinical benefit that lasted for more than 14 months in a patient with pleomorphic xanthoastrocytoma harboring BRAF V600E (PMID: 29632053).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 4852,
                    "name": "pleomorphic xanthoastrocytoma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 11407,
                        "pubMedId": 29632053,
                        "title": "Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29632053"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7874,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BRAF V600E in cell culture and cell line xenograft models (PMID: 19276360).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1095,
                    "therapyName": "GDC0879",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6516,
                        "pubMedId": 19276360,
                        "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7862,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4600,
                    "therapyName": "Dasatinib + Selumetinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1781,
                    "name": "thyroid cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6508,
                        "pubMedId": 27222538,
                        "title": "The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27222538"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9663,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Zolinza (vorinostat) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Rb phosphorylation in culture (PMID: 27924459).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 5121,
                    "therapyName": "PLX4720 + Vorinostat",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 7369,
                        "pubMedId": 27924459,
                        "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 4524,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 3530,
                    "therapyName": "Navitoclax + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 4582,
                        "pubMedId": 25665005,
                        "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 1326,
                "approvalStatus": "Case Reports/Case Series",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 1033,
                        "pubMedId": 24523613,
                        "title": "Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/24523613"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7616,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1711,
                    "therapyName": "Cetuximab + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6445,
                        "pubMedId": 27312529,
                        "title": "Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312529"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7872,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the addition of PAC-1 to Mekinist (trametinib) and Zelboraf (vemurafenib) led to greater levels of caspase-3 activity and apoptosis in melanoma cells harboring BRAF V600E when compared to Zelboraf (vemurafenib) and Mekinist (trametinib) treatment without PAC-1 (PMID: 27297867).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4603,
                    "therapyName": "PAC-1 + Trametinib + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6518,
                        "pubMedId": 27297867,
                        "title": "The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297867"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 686,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In preclinical studies, Encorafenib (LGX818) treatment of human melanoma xenograft models with BRAF V600E significantly decreased Mek activation and resulted in tumor regression (Cancer Res: 72(8) Suppl 1, Abstract #3790).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 417,
                        "pubMedId": null,
                        "title": "Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor",
                        "url": "http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/3790"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 15983,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 30104724).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 7839,
                    "therapyName": "RMC-4550",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "resistant",
                "references": [
                    {
                        "id": 14089,
                        "pubMedId": 30104724,
                        "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 307,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human colon carcinoma cell line (PMID: 22319199).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1002,
                    "therapyName": "RXDX-105",
                    "synonyms": null
                },
                "indication": {
                    "id": 1520,
                    "name": "colon carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 203,
                        "pubMedId": 22319199,
                        "title": "CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/22319199"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16103,
                "approvalStatus": "Phase II",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 46% (12/26, 2 complete response, 10 partial response) in patients with advanced solid tumors harboring BRAF V600E, but only 4% (1/23, 1 partial response) in patients harboring non-V600 BRAF mutations (PMID: 29320312; NCT02091141).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 13171,
                        "pubMedId": 29320312,
                        "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                    }
                ],
                "ampCapAscoEvidenceLevel": "B",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7901,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4606,
                    "therapyName": "PLX7904",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6521,
                        "pubMedId": 26466569,
                        "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/26466569"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7871,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, the combination of PAC-1 and Zelboraf (vemurafenib) resulted in a synergistic effect when treating melanoma cells harboring BRAF V600E in culture and xenograft models, demonstrating increased apoptosis and decreased tumor volume (PMID: 27297867).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4604,
                    "therapyName": "PAC-1 + Vemurafenib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6518,
                        "pubMedId": 27297867,
                        "title": "The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297867"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 466,
                        "name": "RAF Inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 11287,
                "approvalStatus": "FDA approved - On Companion Diagnostic",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a Phase II trial that supported FDA approval, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in patients with non-small cell lung cancer harboring BRAF V600E resulted in an overall response rate of 66.7% (38/57) in previously treated patients and 64% (23/36) in untreated patients, versus 33% (26/78) treated with Tafinlar (dabrafenib) alone (PMID: 27080216, PMID: 27283860, PMID: 28919011; NCT01336634).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6410,
                        "pubMedId": 27080216,
                        "title": "Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27080216"
                    },
                    {
                        "id": 9207,
                        "pubMedId": null,
                        "title": "Updated survival of patients (pts) with previously treated BRAF V600E\u2013mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.",
                        "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9075"
                    },
                    {
                        "id": 10772,
                        "pubMedId": 27283860,
                        "title": "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283860"
                    },
                    {
                        "id": 10773,
                        "pubMedId": 28919011,
                        "title": "Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/28919011"
                    },
                    {
                        "id": 15430,
                        "pubMedId": null,
                        "title": null,
                        "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                    },
                    {
                        "id": 15458,
                        "pubMedId": null,
                        "title": "Tafinlar (dabrafenib) FDA Drug Label",
                        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 12981,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Combination of Mekinist (trametinib) and Tafinlar (dabrafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 3908,
                    "name": "lung non-small cell carcinoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 3335,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 3755,
                        "pubMedId": 23242808,
                        "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 15737,
                "approvalStatus": "Clinical Study",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival  (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "decreased response",
                "references": [
                    {
                        "id": 13705,
                        "pubMedId": 30630828,
                        "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                    }
                ],
                "ampCapAscoEvidenceLevel": "NA",
                "ampCapAscoInferredTier": "NA",
                "relevantTreatmentApproaches": [
                    
                ]
            },
            {
                "id": 1343,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 888,
                    "therapyName": "Refametinib",
                    "synonyms": null
                },
                "indication": {
                    "id": 9256,
                    "name": "colorectal cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 877,
                        "pubMedId": 19706763,
                        "title": "RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/19706763"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 9108,
                "approvalStatus": "Preclinical - Cell culture",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 4902,
                    "therapyName": "Everolimus + PLX4720",
                    "synonyms": null
                },
                "indication": {
                    "id": 3070,
                    "name": "malignant glioma",
                    "source": "DOID"
                },
                "responseType": "predicted - sensitive",
                "references": [
                    {
                        "id": 6921,
                        "pubMedId": 27217440,
                        "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 16980,
                "approvalStatus": "Guideline",
                "evidenceType": "Actionable",
                "efficacyEvidence": "Braftovi (encorafenib), Mektovi (binimetinib), Vectibix (panitumumab), combination therapy is included in guidelines as a second-line therapy for advanced or metastatic colon cancer patients harboring BRAF V600E (NCCN.org).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 8361,
                    "therapyName": "Binimetinib + Encorafenib + Panitumumab",
                    "synonyms": null
                },
                "indication": {
                    "id": 219,
                    "name": "colon cancer",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 10889,
                        "pubMedId": null,
                        "title": "NCCN.org",
                        "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                    }
                ],
                "ampCapAscoEvidenceLevel": "A",
                "ampCapAscoInferredTier": "I",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 7823,
                "approvalStatus": "Preclinical - Cell line xenograft",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of melanoma cell lines harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models of BRAF V600E-positive melanoma, including models with BRAF-inhibitor resistance (PMID: 25873592).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 1059,
                    "therapyName": "BI-847325",
                    "synonyms": null
                },
                "indication": {
                    "id": 1909,
                    "name": "melanoma",
                    "source": "DOID"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 6506,
                        "pubMedId": 25873592,
                        "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 467,
                        "name": "MEK inhibitor (Pan)",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 2,
                        "name": "MEK1 Inhibitor",
                        "profileName": "BRAF V600E"
                    },
                    {
                        "id": 7,
                        "name": "MEK2 Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            },
            {
                "id": 6832,
                "approvalStatus": "Preclinical",
                "evidenceType": "Actionable",
                "efficacyEvidence": "In a preclinical study, RAF265 inhibited Erk phosphorylation and cell proliferation in BRAF V600E expressing cells in culture (PMID: 20538618).",
                "molecularProfile": {
                    "id": 1,
                    "profileName": "BRAF V600E"
                },
                "therapy": {
                    "id": 884,
                    "therapyName": "RAF265",
                    "synonyms": null
                },
                "indication": {
                    "id": 10000003,
                    "name": "Advanced Solid Tumor",
                    "source": "JAX"
                },
                "responseType": "sensitive",
                "references": [
                    {
                        "id": 5859,
                        "pubMedId": 20538618,
                        "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                        "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                    }
                ],
                "ampCapAscoEvidenceLevel": "D",
                "ampCapAscoInferredTier": "II",
                "relevantTreatmentApproaches": [
                    {
                        "id": 1,
                        "name": "BRAF Inhibitor",
                        "profileName": "BRAF V600E"
                    }
                ]
            }
        ]
    }
}